Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Disease_description.refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	SIFT_score	SIFT_converted_rankscore	SIFT_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST3_score	VEST3_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	CADD_raw	CADD_raw_rankscore	CADD_phred	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6_gene	GTEx_V6_tissue	Otherinfo
chr1	911928	911928	G	C	exonic	PERM1	.	synonymous SNV	PERM1:NM_001291366:exon3:c.C2226G:p.T742T,PERM1:NM_001291367:exon4:c.C1944G:p.T648T	.	.	.	.	0.06703	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr1	911928	chr1:911928	G	C	.	PASS	AN=0;DP=45	GT	0/1
chr1	1159252	1159252	C	A	exonic	SDF4	.	nonsynonymous SNV	SDF4:NM_016176:exon3:c.G423T:p.E141D,SDF4:NM_016547:exon3:c.G423T:p.E141D	0.001309827	0.858724277	0.139965896	.	0.10366	0.35502	-0.598810865	18.13517339	109.15684	2.26829	0.074	0.346	T	0.683	0.508	P	0.306	0.519	B	0.000	0.843	D	1.000	0.530	D	1.86	0.494	L	3.05	0.087	T	-0.8	0.221	N	0.391	0.528	-0.914	0.464	T	0.179	0.525	T	0.025	0.480	T	3.092	0.431	22.5	0.988	0.453	0.889	0.487	D	c	-0.298	-0.371	0.038	0.143	0.707	0.730	0	-0.070	0.130	1.032	0.296	-0.009	0.132	1.000	0.715	0.137	0.201	9.532	0.382	EF-hand domain|EF-hand domain pair	.	.	0.5	.	70	chr1	1159252	chr1:1159252	C	A	.	PASS	AN=0;DP=70	GT	0/1
chr1	1920345	1920345	C	T	exonic	CFAP74	.	synonymous SNV	CFAP74:NM_001304360:exon3:c.G135A:p.V45V	.	.	.	.	0.12614	0.09843	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	166	chr1	1920345	chr1:1920345	C	T	.	PASS	AN=0;DP=166	GT	0/1
chr1	12898387	12898387	G	A	intergenic	PRAMEF11;HNRNPCL1	dist=7123;dist=8843	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	81	chr1	12898387	chr1:12898387	G	A	.	PASS	AN=0;DP=81	GT	0/1
chr1	14107213	14107213	C	T	exonic	PRDM2	.	nonsynonymous SNV	PRDM2:NM_001007257:exon3:c.C2320T:p.P774S,PRDM2:NM_012231:exon8:c.C2923T:p.P975S,PRDM2:NM_015866:exon8:c.C2923T:p.P975S	0.995040619	0.004959381	1.78E-10	.	0.28355	0.21546	-0.553188106	19.81009672	615.77007	5.0118	0.019	0.501	D	0.098	0.240	B	0.038	0.234	B	0.009	0.305	N	0.850	0.810	D	1.555	0.395	L	4.86	0.016	T	-0.53	0.164	N	0.245	0.299	-0.944	0.419	T	0.006	0.022	T	0.007	0.188	T	1.962	0.297	15.97	0.991	0.512	0.479	0.278	N	c	-0.577	-0.484	1.000	0.434	0.706	0.609	0	3.0	0.336	0.865	0.274	0.038	0.153	0.094	0.225	0.926	0.400	11.450	0.492	.	.	.	0.5	71	88	chr1	14107213	chr1:14107213	C	T	71	PASS	AN=2;DP=88	GT	0/1
chr1	16262553	16262553	C	T	exonic	SPEN	.	nonsynonymous SNV	SPEN:NM_015001:exon11:c.C9818T:p.T3273I	1	3.70E-14	1.69E-35	.	0.87812	0.15972	-2.307490096	1.209011559	1380.73788	6.9638	0.006	0.614	D	0.996	0.670	D	0.931	0.649	D	.	.	.	0.991	0.240	N	2.08	0.576	M	3.05	0.087	T	-1.85	0.433	N	0.247	0.332	-1.045	0.157	T	0.051	0.218	T	0.015	0.350	T	6.043	0.832	28.0	0.996	0.766	0.934	0.580	D	c	0.464	0.469	1.000	0.747	0.732	0.924	0	5.18	0.710	3.790	0.549	0.836	0.341	0.998	0.411	0.782	0.331	17.659	0.880	.	.	.	0.5	.	84	chr1	16262553	chr1:16262553	C	T	.	PASS	AN=0;DP=84	GT	0/1
chr1	16957374	16957374	C	T	ncRNA_intronic	CROCCP2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	135	chr1	16957374	chr1:16957374	C	T	.	PASS	AN=0;DP=135	GT	0/1
chr1	19412750	19412750	C	T	exonic	UBR4	.	nonsynonymous SNV	UBR4:NM_020765:exon101:c.G14702A:p.R4901Q	1	2.43E-23	4.94E-62	.	0.25731	0.12662	-7.504914615	0.011795235	2894.47418	10.19251	0.0	0.912	D	0.997	0.689	D	0.968	0.701	D	0.000	0.843	D	1	0.810	D	2.25	0.640	M	1.37	0.342	T	-3.56	0.734	D	0.659	0.703	-0.571	0.660	T	0.256	0.626	T	0.086	0.747	D	8.446	0.958	35	0.999	0.999	0.962	0.679	D	c	0.877	0.858	1.000	0.747	0.707	0.730	0	5.75	0.904	7.568	0.814	0.852	0.362	1.000	0.715	0.993	0.574	18.521	0.909	.	.	.	0.5	.	46	chr1	19412750	chr1:19412750	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr1	21799967	21799967	A	T	exonic	NBPF3	.	nonsynonymous SNV	NBPF3:NM_001256417:exon6:c.A619T:p.N207Y,NBPF3:NM_001256416:exon7:c.A829T:p.N277Y,NBPF3:NM_032264:exon7:c.A829T:p.N277Y,NBPF3:NM_001330381:exon11:c.A661T:p.N221Y	1.98E-11	0.378787942	0.621212058	.	0.06699	.	3.60019308	99.52819061	1664.61558	7.53254	0.093	0.682	T	0.999	0.764	D	0.986	0.754	D	.	.	.	1	0.090	N	2.255	0.644	M	3.43	0.055	T	-5.21	0.861	D	0.052	0.494	-1.044	0.162	T	0.034	0.148	T	0.001	0.005	T	1.153	0.205	11.50	0.538	0.049	0.001	0.006	N	c	-0.688	-1.038	0.006	0.111	0.615	0.372	0	-1.8	0.074	-1.030	0.037	-0.882	0.027	0.000	0.063	0.000	0.016	2.840	0.051	Neuroblastoma breakpoint family (NBPF) domain	.	.	0.5	.	42	chr1	21799967	chr1:21799967	A	T	.	PASS	AN=0;DP=42	GT	0/1
chr1	27861282	27861282	C	T	UTR3	AHDC1	NM_001029882:c.*189G>A	.	.	0.999431448	0.000568552	5.41E-10	DISEASE: Mental retardation, autosomal dominant 25 (MRD25) [MIM:615829]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD25 additional features include mild dysmorphism, hypotonia, delayed psychomotor development with absent or poor expressive language, hypoplasia of the corpus callosum, simplified gyral pattern, and delayed myelination. {ECO:0000269|PubMed:24791903}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09286	.	-1.095046929	6.97688134	544.59826	4.74752	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	71	chr1	27861282	chr1:27861282	C	T	.	PASS	AN=0;DP=71	GT	0/1
chr1	37958235	37958235	G	A	UTR3	MEAF6	NM_022756:c.*1465C>T;NM_001270876:c.*1135C>T;NM_001270875:c.*1465C>T	.	.	0.730388139	0.269048652	0.000563209	DISEASE: Note=A chromosomal aberration involving MEAF6 may be a cause of endometrial stromal tumors. Translocation t(1;6)(p34;p21) with PHF1. {ECO:0000269|PubMed:22761769}.; 	0.18507	0.10264	-0.09720619	46.20193442	5.77712	0.21811	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	112	chr1	37958235	chr1:37958235	G	A	64	PASS	AN=2;DP=112	GT	0/1
chr1	38462470	38462470	G	A	UTR3	FHL3	NM_004468:c.*607C>T;NM_001243878:c.*607C>T	.	.	0.534417266	0.462285973	0.003296761	.	0.29794	0.11106	0.284856336	71.40835103	213.429	3.15204	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	100	chr1	38462470	chr1:38462470	G	A	.	PASS	AN=0;DP=100	GT	0/1
chr1	38462985	38462987	GGC	-	UTR3	FHL3	NM_004468:c.*92_*90delGCC;NM_001243878:c.*92_*90delGCC	.	.	0.534417266	0.462285973	0.003296761	.	0.29794	0.11106	0.284856336	71.40835103	213.429	3.15204	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	86	chr1	38462984	chr1:38462984	TGGC	T	42	PASS	AN=2;DP=86	GT	0/1
chr1	48231682	48231682	C	T	exonic	TRABD2B	.	synonymous SNV	TRABD2B:NM_001194986:exon7:c.G1446A:p.Q482Q	0.370916244	0.480003521	0.149080235	.	.	.	.	.	725.47613	5.34688	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	85	chr1	48231682	chr1:48231682	C	T	70	PASS	AN=2;DP=85	GT	0/1
chr1	67154855	67154881	CCACTCCTTTGGTTCCTTGCAGAAGTA	-	exonic	SGIP1	.	nonframeshift deletion	SGIP1:NM_001308203:exon13:c.743_769del:p.L251_P259del,SGIP1:NM_001350218:exon14:c.767_793del:p.L259_P267del,SGIP1:NM_001350217:exon16:c.1352_1378del:p.L454_P462del,SGIP1:NM_032291:exon16:c.1340_1366del:p.L450_P458del	0.999651093	0.000348907	6.74E-12	.	0.55441	0.08704	-1.083859071	7.195093182	3375.22155	11.12347	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	11.48	22	chr1	67154854	chr1:67154854	GCCACTCCTTTGGTTCCTTGCAGAAGTA	G	11.48	PASS	AN=0;DP=22	GT	0/1
chr1	74901656	74901656	C	T	intronic	FPGT-TNNI3K;TNNI3K	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr1	74901656	chr1:74901656	C	T	.	PASS	AN=0;DP=40	GT	0/1
chr1	83920300	83920300	-	C	ncRNA_intronic	LINC01712	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	11	chr1	83920300	chr1:83920300	A	AC	42	PASS	AN=2;DP=11	GT	0/1
chr1	84956162	84956162	T	-	intronic	RPF1	.	.	.	9.48E-07	0.528911426	0.471087626	.	0.17412	0.10595	0.997633954	90.65227648	2647.98942	9.65398	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	9	chr1	84956161	chr1:84956161	CT	C	42	PASS	AN=2;DP=9	GT	0/1
chr1	85014531	85014531	G	A	exonic	SPATA1	.	nonsynonymous SNV	SPATA1:NM_001310156:exon11:c.G1075A:p.V359I	.	.	.	.	0.10403	0.10073	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr1	85014531	chr1:85014531	G	A	.	PASS	AN=0;DP=41	GT	0/1
chr1	92475035	92475035	C	T	intronic	BRDT	.	.	.	2.47E-06	0.999058891	0.000938637	.	0.14403	0.30507	0.782621089	87.25524888	2880.26845	10.16474	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr1	92475035	chr1:92475035	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr1	100671699	100671699	G	-	intronic	DBT	.	.	.	0.000147622	0.964498843	0.035353535	DISEASE: Note=Patients with primary biliary cirrhosis (PBC) show autoantibodies against the E2 component of branched-chain alpha- keto acid dehydrogenase complex. PBC is a chronic, progressive cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients serum. It manifests with inflammatory obliteration of intra-hepatic bile duct, leading to liver cell damage and cirrhosis. {ECO:0000269|PubMed:2908870, ECO:0000269|PubMed:7543435, ECO:0000269|PubMed:9141421}.; DISEASE: Maple syrup urine disease 2 (MSUD2) [MIM:248600]: A metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. {ECO:0000269|PubMed:1847055, ECO:0000269|PubMed:9621512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.39075	0.32097	0.817616644	87.95116773	173.95713	2.87132	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	18	chr1	100671698	chr1:100671698	AG	A	58	PASS	AN=2;DP=18	GT	0/1
chr1	103354985	103354985	A	-	intronic	COL11A1	.	.	.	0.999980608	1.94E-05	6.79E-22	DISEASE: Stickler syndrome 2 (STL2) [MIM:604841]: An autosomal dominant form of Stickler syndrome, an inherited disorder that associates ocular signs with more or less complete forms of Pierre Robin sequence, bone disorders and sensorineural deafness. Ocular disorders may include juvenile cataract, myopia, strabismus, vitreoretinal or chorioretinal degeneration, retinal detachment, and chronic uveitis. Pierre Robin sequence includes an opening in the roof of the mouth (a cleft palate), a large tongue (macroglossia), and a small lower jaw (micrognathia). Bones are affected by slight platyspondylisis and large, often defective epiphyses. Juvenile joint laxity is followed by early signs of arthrosis. The degree of hearing loss varies among affected individuals and may become more severe over time. Syndrome expressivity is variable. {ECO:0000269|PubMed:20513134, ECO:0000269|PubMed:8872475}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Marshall syndrome (MRSHS) [MIM:154780]: An autosomal dominant disorder characterized by ocular abnormalities, deafness, craniofacial anomalies, and anhidrotic ectodermal dysplasia. Clinical features include short stature; flat or retruded midface with short, depressed nose, flat nasal bridge and anteverted nares; cleft palate with or without the Pierre Robin sequence; appearance of large eyes with ocular hypertelorism; cataracts, either congenital or juvenile; esotropia; high myopia; sensorineural hearing loss; spondyloepiphyseal abnormalities; calcification of the falx cerebri; ectodermal abnormalities, including defects in sweating and dental structures. {ECO:0000269|PubMed:10486316}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Fibrochondrogenesis 1 (FBCG1) [MIM:228520]: A severe short-limbed skeletal dysplasia characterized by broad long-bone metaphyses, pear-shaped vertebral bodies, and characteristic morphology of the growth plate, in which the chondrocytes have a fibroblastic appearance and there are regions of fibrous cartilage extracellular matrix. Clinical features include a flat midface with a small nose and anteverted nares, significant shortening of all limb segments but relatively normal hands and feet, and a small bell-shaped thorax with a protuberant abdomen. {ECO:0000269|PubMed:21035103}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.35429	0.34658	-0.360177779	28.64472753	7076.86232	18.07025	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	63	chr1	103354984	chr1:103354984	GA	G	42	PASS	AN=2;DP=63	GT	0/1
chr1	103355033	103355033	G	A	exonic	COL11A1	.	nonsynonymous SNV	COL11A1:NM_080630:exon57:c.C4094T:p.S1365F,COL11A1:NM_001190709:exon58:c.C4325T:p.S1442F,COL11A1:NM_001854:exon59:c.C4442T:p.S1481F,COL11A1:NM_080629:exon59:c.C4478T:p.S1493F	0.999980608	1.94E-05	6.79E-22	DISEASE: Stickler syndrome 2 (STL2) [MIM:604841]: An autosomal dominant form of Stickler syndrome, an inherited disorder that associates ocular signs with more or less complete forms of Pierre Robin sequence, bone disorders and sensorineural deafness. Ocular disorders may include juvenile cataract, myopia, strabismus, vitreoretinal or chorioretinal degeneration, retinal detachment, and chronic uveitis. Pierre Robin sequence includes an opening in the roof of the mouth (a cleft palate), a large tongue (macroglossia), and a small lower jaw (micrognathia). Bones are affected by slight platyspondylisis and large, often defective epiphyses. Juvenile joint laxity is followed by early signs of arthrosis. The degree of hearing loss varies among affected individuals and may become more severe over time. Syndrome expressivity is variable. {ECO:0000269|PubMed:20513134, ECO:0000269|PubMed:8872475}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Marshall syndrome (MRSHS) [MIM:154780]: An autosomal dominant disorder characterized by ocular abnormalities, deafness, craniofacial anomalies, and anhidrotic ectodermal dysplasia. Clinical features include short stature; flat or retruded midface with short, depressed nose, flat nasal bridge and anteverted nares; cleft palate with or without the Pierre Robin sequence; appearance of large eyes with ocular hypertelorism; cataracts, either congenital or juvenile; esotropia; high myopia; sensorineural hearing loss; spondyloepiphyseal abnormalities; calcification of the falx cerebri; ectodermal abnormalities, including defects in sweating and dental structures. {ECO:0000269|PubMed:10486316}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Fibrochondrogenesis 1 (FBCG1) [MIM:228520]: A severe short-limbed skeletal dysplasia characterized by broad long-bone metaphyses, pear-shaped vertebral bodies, and characteristic morphology of the growth plate, in which the chondrocytes have a fibroblastic appearance and there are regions of fibrous cartilage extracellular matrix. Clinical features include a flat midface with a small nose and anteverted nares, significant shortening of all limb segments but relatively normal hands and feet, and a small bell-shaped thorax with a protuberant abdomen. {ECO:0000269|PubMed:21035103}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.35429	0.34658	-0.360177779	28.64472753	7076.86232	18.07025	0.11	0.295	T	0.036	0.337	B	0.047	0.363	B	0.002	0.367	N	0.999	0.466	D	1.09	0.274	L	-3.22	0.934	D	-2.94	0.640	D	0.376	0.437	-0.051	0.812	T	0.494	0.808	T	0.069	0.708	D	2.773	0.394	21.2	0.979	0.365	0.983	0.814	D	c	0.080	0.274	0.994	0.336	0.706	0.609	0	5.46	0.799	6.902	0.753	1.048	0.713	1.000	0.715	0.992	0.562	13.591	0.613	.	.	.	0.5	39	58	chr1	103355033	chr1:103355033	G	A	39	PASS	AN=2;DP=58	GT	0/1
chr1	110173005	110173005	C	T	exonic	AMPD2	.	nonsynonymous SNV	AMPD2:NM_203404:exon14:c.C1939T:p.P647S,AMPD2:NM_001308170:exon15:c.C2071T:p.P691S,AMPD2:NM_001257361:exon16:c.C1942T:p.P648S,AMPD2:NM_004037:exon16:c.C2296T:p.P766S,AMPD2:NM_139156:exon16:c.C2053T:p.P685S,AMPD2:NM_001257360:exon17:c.C2296T:p.P766S	0.008542497	0.991346093	0.00011141	DISEASE: Spastic paraplegia 63, autosomal recessive (SPG63) [MIM:615686]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. {ECO:0000269|PubMed:24482476}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.23763	0.21683	-1.462333834	3.786270347	1844.00657	7.9205	0.0	0.912	D	1.0	0.899	D	0.999	0.971	D	0.000	0.843	D	1	0.810	D	3.905	0.962	H	-4.51	0.977	D	-6.6	0.956	D	0.73	0.933	0.459	0.900	D	0.587	0.852	D	0.612	0.966	D	6.600	0.907	31	0.999	0.986	0.926	0.558	D	c	0.629	0.609	1.000	0.747	0.752	0.988	0	4.65	0.575	7.855	0.852	0.934	0.450	1.000	0.715	0.998	0.697	17.320	0.871	Adenosine/AMP deaminase domain|Metal-dependent hydrolase	.	.	0.5	.	82	chr1	110173005	chr1:110173005	C	T	.	PASS	AN=0;DP=82	GT	0/1
chr1	115399860	115399861	TT	-	exonic	SYCP1	.	frameshift deletion	SYCP1:NM_001282541:exon4:c.201_202del:p.L68Tfs*3,SYCP1:NM_001282542:exon4:c.201_202del:p.L68Tfs*3,SYCP1:NM_003176:exon4:c.201_202del:p.L68Tfs*3	0.949997702	0.050002296	2.17E-09	.	0.08531	.	0.246221394	69.56829441	212.38101	3.14424	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	41	chr1	115399859	chr1:115399859	CTT	C	62	PASS	AN=2;DP=41	GT	0/1
chr1	117078556	117078556	G	A	intronic	CD58	.	.	.	0.299199171	0.681299599	0.019501229	.	0.16155	0.20638	0.61555716	83.13871196	82.3264	1.92612	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr1	117078556	chr1:117078556	G	A	.	PASS	AN=0;DP=36	GT	0/1
chr1	117078597	117078597	G	A	exonic	CD58	.	synonymous SNV	CD58:NM_001144822:exon3:c.C618T:p.I206I,CD58:NM_001779:exon3:c.C618T:p.I206I	0.299199171	0.681299599	0.019501229	.	0.16155	0.20638	0.61555716	83.13871196	82.3264	1.92612	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr1	117078597	chr1:117078597	G	A	.	PASS	AN=0;DP=31	GT	0/1
chr1	118166754	118166754	G	A	UTR3	FAM46C	NM_017709:c.*88G>A	.	.	0.523539098	0.459890812	0.01657009	.	0.56632	0.11049	-0.113792788	45.25831564	50.1058	1.38975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr1	118166754	chr1:118166754	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr1	120612041	120612046	CCGCCG	-	UTR5	NOTCH2	NM_024408:c.-21_-26delCGGCGG;NM_001200001:c.-21_-26delCGGCGG	.	.	0.999999993	6.75E-09	4.50E-24	DISEASE: Alagille syndrome 2 (ALGS2) [MIM:610205]: A form of Alagille syndrome, an autosomal dominant multisystem disorder. It is clinically defined by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems. {ECO:0000269|PubMed:16773578}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hajdu-Cheney syndrome (HJCYS) [MIM:102500]: A rare skeletal disorder characterized by the association of facial anomalies, acro-osteolysis, general osteoporosis, insufficient ossification of the skull, and periodontal disease (premature loss of permanent teeth). Other features include cleft palate, congenital heart defects, polycystic kidneys, orthopedic problems and anomalies of the genitalia, intestines and eyes. {ECO:0000269|PubMed:21378985, ECO:0000269|PubMed:21378989}. Note=The disease is caused by mutations affecting the gene represented in this entry. NOTCH2 mutations associated with Hajdu- Cheney syndrome cluster to the last coding exon of the gene. This suggests that the mutant mRNA products may escape nonsense- mediated decay and the resulting truncated NOTCH2 proteins act in a gain-of-function manner.; 	0.95316	0.43816	-1.819260363	2.14673272	449.73773	4.40739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	56	chr1	120612040	chr1:120612040	TCCGCCG	T,TCCG	41	PASS	AN=2;DP=56	GT	0/1
chr1	120612044	120612046	CCG	-	UTR5	NOTCH2	NM_024408:c.-24_-26delCGG;NM_001200001:c.-24_-26delCGG	.	.	0.999999993	6.75E-09	4.50E-24	DISEASE: Alagille syndrome 2 (ALGS2) [MIM:610205]: A form of Alagille syndrome, an autosomal dominant multisystem disorder. It is clinically defined by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems. {ECO:0000269|PubMed:16773578}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hajdu-Cheney syndrome (HJCYS) [MIM:102500]: A rare skeletal disorder characterized by the association of facial anomalies, acro-osteolysis, general osteoporosis, insufficient ossification of the skull, and periodontal disease (premature loss of permanent teeth). Other features include cleft palate, congenital heart defects, polycystic kidneys, orthopedic problems and anomalies of the genitalia, intestines and eyes. {ECO:0000269|PubMed:21378985, ECO:0000269|PubMed:21378989}. Note=The disease is caused by mutations affecting the gene represented in this entry. NOTCH2 mutations associated with Hajdu- Cheney syndrome cluster to the last coding exon of the gene. This suggests that the mutant mRNA products may escape nonsense- mediated decay and the resulting truncated NOTCH2 proteins act in a gain-of-function manner.; 	0.95316	0.43816	-1.819260363	2.14673272	449.73773	4.40739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	56	chr1	120612040	chr1:120612040	TCCGCCG	T,TCCG	41	PASS	AN=2;DP=56	GT	0/1
chr1	148252019	148252019	G	C	exonic	NBPF14;NBPF9	.	nonsynonymous SNV	NBPF9:NM_001277444:exon25:c.C3192G:p.D1064E,NBPF14:NM_015383:exon66:c.C8316G:p.D2772E	.	.	.	.	.	.	.	.	.	.	.	.	.	0.795	0.520	P	0.739	0.573	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.164	0.198	-1.067	0.100	T	0.022	0.094	T	0.001	0.014	T	2.112	0.315	16.93	0.973	0.330	0.006	0.026	N	c	-0.547	-0.839	0.023	0.135	0.706	0.609	0	0.109	0.138	0.337	0.194	0.494	0.279	0.001	0.137	0.001	0.043	.	.	Neuroblastoma breakpoint family (NBPF) domain	.	.	0.5	74	107	chr1	148252019	chr1:148252019	G	C	74	PASS	AN=2;DP=107	GT	0/1
chr1	152800062	152800062	T	C	exonic	LCE1A	.	synonymous SNV	LCE1A:NM_178348:exon1:c.T114C:p.P38P	0.000409834	0.234194562	0.765395605	.	0.25431	.	0.03689118	56.64071715	25.22558	0.8248	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	170	chr1	152800062	chr1:152800062	T	C	71	PASS	AN=2;DP=170	GT	0/1
chr1	154963016	154963016	G	C	intronic	FLAD1	.	.	.	0.091793511	0.906439743	0.001766745	.	0.11392	0.23178	-1.043396569	7.71408351	87.62766	1.99904	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	26	chr1	154963016	chr1:154963016	G	C	42	PASS	AN=2;DP=26	GT	0/1
chr1	158637829	158637829	C	T	exonic	SPTA1	.	synonymous SNV	SPTA1:NM_003126:exon15:c.G1857A:p.R619R	5.85E-05	0.99994147	3.90E-16	DISEASE: Elliptocytosis 2 (EL2) [MIM:130600]: A Rhesus-unlinked form of hereditary elliptocytosis, a genetically heterogeneous, autosomal dominant hematologic disorder. It is characterized by variable hemolytic anemia and elliptical or oval red cell shape. {ECO:0000269|PubMed:1541680, ECO:0000269|PubMed:1638030, ECO:0000269|PubMed:1679439, ECO:0000269|PubMed:1878597, ECO:0000269|PubMed:2384601, ECO:0000269|PubMed:2568861, ECO:0000269|PubMed:2568862, ECO:0000269|PubMed:2794061, ECO:0000269|PubMed:7772539, ECO:0000269|PubMed:8018926, ECO:0000269|PubMed:8193371, ECO:0000269|PubMed:8364215}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hereditary pyropoikilocytosis (HPP) [MIM:266140]: Autosomal recessive hematologic disorder characterized by hemolytic anemia, microspherocytosis, poikilocytosis, and an unusual thermal sensitivity of red cells. {ECO:0000269|PubMed:1878597}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spherocytosis 3 (SPH3) [MIM:270970]: Spherocytosis is a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. SPH3 is characterized by severe hemolytic anemia. Inheritance is autosomal recessive. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.20565	0.08686	4.849637631	99.79358339	7837.04606	19.05718	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr1	158637829	chr1:158637829	C	T	.	PASS	AN=0;DP=18	GT	0/1
chr1	161102192	161102192	C	T	UTR5	DEDD	NM_001039712:c.-7940G>A	.	.	0.86950321	0.130127431	0.00036936	.	0.4811	0.13398	-0.05129383	49.75819769	50.2724	1.39373	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	80	chr1	161102192	chr1:161102192	C	T	.	PASS	AN=0;DP=80	GT	0/1
chr1	175116147	175116148	CA	-	exonic	TNN	.	frameshift deletion	TNN:NM_022093:exon19:c.3840_3841del:p.S1280Rfs*154	5.19E-15	0.506715096	0.493284904	.	0.17043	.	1.51017302	95.42934654	5625.2664	15.52544	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	84	chr1	175116146	chr1:175116146	GCA	G,GA	72	PASS	AN=2;DP=84	GT	0/1
chr1	175116147	175116147	C	-	exonic	TNN	.	frameshift deletion	TNN:NM_022093:exon19:c.3840delC:p.S1280Rfs*12	5.19E-15	0.506715096	0.493284904	.	0.17043	.	1.51017302	95.42934654	5625.2664	15.52544	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	84	chr1	175116146	chr1:175116146	GCA	G,GA	72	PASS	AN=2;DP=84	GT	0/1
chr1	204192704	204192704	G	A	exonic	PLEKHA6	.	nonsynonymous SNV	PLEKHA6:NM_014935:exon22:c.C3041T:p.A1014V	0.98196907	0.018030926	4.22E-09	.	0.21929	0.11756	-1.207107349	5.726586459	192.56504	3.00941	0.427	0.096	T	0.997	0.689	D	0.97	0.706	D	0.079	0.210	N	0.979	0.395	D	0.315	0.103	N	3.0	0.092	T	0.74	0.023	N	0.406	0.464	-0.932	0.438	T	0.034	0.145	T	0.024	0.475	T	5.616	0.765	26.6	0.999	0.955	0.853	0.441	D	c	0.338	0.397	1.000	0.747	0.706	0.609	0	4.72	0.591	4.590	0.605	1.048	0.713	1.000	0.715	1.000	0.888	15.846	0.786	.	.	.	0.5	.	66	chr1	204192704	chr1:204192704	G	A	.	PASS	AN=0;DP=66	GT	0/1
chr1	217784432	217784432	C	-	intronic	GPATCH2	.	.	.	9.66E-05	0.986025695	0.013877705	.	0.35805	.	0.108486928	61.90728946	309.35921	3.7445	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	18	chr1	217784431	chr1:217784431	AC	A	44	PASS	AN=2;DP=18	GT	0/1
chr1	220101104	220101104	G	A	ncRNA_intronic	RNU5F-1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr1	220101104	chr1:220101104	G	A	.	PASS	AN=0;DP=25	GT	0/1
chr2	10139226	10139226	C	-	intronic	GRHL1	.	.	.	0.983150779	0.016849134	8.72E-08	.	0.18056	0.20109	-0.113792788	45.25831564	1942.58495	8.11174	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	55	chr2	10139225	chr2:10139225	AC	A	65	PASS	AN=2;DP=55	GT	0/1
chr2	14778252	14778252	C	A	UTR3	FAM84A	NM_145175:c.*3270C>A	.	.	0.087816303	0.762868639	0.149315058	.	0.15023	0.08134	-0.075159878	47.78839349	16.9347	0.59676	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	77	chr2	14778252	chr2:14778252	C	A	.	PASS	AN=0;DP=77	GT	0/1
chr2	24507685	24507685	G	T	exonic	ITSN2	.	nonsynonymous SNV	ITSN2:NM_001348185:exon17:c.C1891A:p.Q631K,ITSN2:NM_006277:exon17:c.C1891A:p.Q631K,ITSN2:NM_147152:exon17:c.C1891A:p.Q631K,ITSN2:NM_001348181:exon18:c.C1849A:p.Q617K	0.024433691	0.975566309	5.52E-13	.	0.30109	0.18256	-0.512707122	21.42014626	4780.84117	14.02023	0.211	0.419	T	0.4	0.330	B	0.225	0.363	B	.	.	.	0.851	0.810	D	0.345	0.112	N	0.29	0.589	T	-0.51	0.160	N	0.556	0.591	-0.788	0.559	T	0.211	0.572	T	0.019	0.412	T	2.771	0.394	21.2	0.977	0.346	0.870	0.461	D	c	0.261	0.397	1.000	0.500	0.476	0.093	0	5.5	0.813	6.493	0.734	1.048	0.713	1.000	0.715	1.000	0.888	19.784	0.964	.	.	.	0.5	.	30	chr2	24507685	chr2:24507685	G	T	.	PASS	AN=0;DP=30	GT	0/1
chr2	24507738	24507738	C	T	intronic	ITSN2	.	.	.	0.024433691	0.975566309	5.52E-13	.	0.30109	0.18256	-0.512707122	21.42014626	4780.84117	14.02023	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr2	24507738	chr2:24507738	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr2	32515614	32515614	G	T	exonic	YIPF4	.	stopgain	YIPF4:NM_032312:exon2:c.G142T:p.E48X	0.019788591	0.902081655	0.078129753	.	0.25391	0.10849	0.369407109	74.95281906	43.18158	1.24746	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.498	0.975	37	0.996	0.729	0.981	0.792	D	c	0.897	0.760	1.000	0.747	0.706	0.609	0	4.48	0.538	9.020	0.931	0.953	0.551	1.000	0.715	1.000	0.888	15.872	0.788	.	.	.	0.5	.	33	chr2	32515614	chr2:32515614	G	T	.	PASS	AN=0;DP=33	GT	0/1
chr2	68357928	68357928	T	-	UTR3	WDR92	NM_138458:c.*442delA	.	.	0.805659459	0.194119638	0.000220902	.	.	.	0.084621747	60.31493277	1268.45257	6.71084	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	91	chr2	68357927	chr2:68357927	CT	C	55	PASS	AN=2;DP=91	GT	0/1
chr2	71265235	71265235	G	T	intergenic	OR7E91P;NAGK	dist=8175;dist=30173	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	100	chr2	71265235	chr2:71265235	G	T	.	PASS	AN=0;DP=100	GT	0/1
chr2	97711806	97711806	A	G	intergenic	FAM178B;FAHD2B	dist=59505;dist=37517	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	33	chr2	97711806	chr2:97711806	A	G	62	PASS	AN=2;DP=33	GT	0/1
chr2	105892143	105892143	C	T	exonic	TGFBRAP1	.	synonymous SNV	TGFBRAP1:NM_001142621:exon8:c.G1539A:p.V513V,TGFBRAP1:NM_001328646:exon8:c.G1539A:p.V513V,TGFBRAP1:NM_004257:exon8:c.G1539A:p.V513V	0.129423466	0.870378795	0.000197739	.	0.07447	0.23492	-1.03794674	7.832035858	126.08397	2.44361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr2	105892143	chr2:105892143	C	T	.	PASS	AN=0;DP=20	GT	0/1
chr2	107032238	107032238	A	G	intronic	RGPD3	.	.	.	.	.	.	.	.	.	.	.	3258.22851	10.87204	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	38	chr2	107032238	chr2:107032238	A	G	74	PASS	AN=2;DP=38	GT	0/1
chr2	113138326	113138326	C	T	intronic	RGPD5;RGPD8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	84	chr2	113138326	chr2:113138326	C	T	.	PASS	AN=0;DP=84	GT	0/1
chr2	145277696	145277696	C	T	ncRNA_intronic	ZEB2-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	14	chr2	145277696	chr2:145277696	C	T	.	PASS	AN=0;DP=14	GT	0/1
chr2	145277718	145277718	C	T	ncRNA_intronic	ZEB2-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	13	chr2	145277718	chr2:145277718	C	T	.	PASS	AN=0;DP=13	GT	0/1
chr2	171608612	171608612	G	A	ncRNA_intronic	LOC101926913	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	35	chr2	171608612	chr2:171608612	G	A	.	PASS	AN=0;DP=35	GT	0/1
chr2	183841601	183841601	C	G	intronic	NCKAP1	.	.	.	0.999999991	9.29E-09	5.84E-21	.	0.53149	0.18619	-1.199555187	5.761972163	23.37723	0.77966	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr2	183841601	chr2:183841601	C	G	.	PASS	AN=0;DP=31	GT	0/1
chr2	190323402	190323402	C	T	intronic	WDR75	.	.	.	0.566494634	0.433504487	8.79E-07	.	0.42701	0.10537	-1.219785504	5.602736494	110.68114	2.29156	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr2	190323402	chr2:190323402	C	T	.	PASS	AN=0;DP=28	GT	0/1
chr2	204137443	204137443	C	T	exonic	CYP20A1	.	synonymous SNV	CYP20A1:NM_177538:exon6:c.C651T:p.N217N	7.41E-10	0.250664384	0.749335615	.	0.17142	0.20477	0.264628794	70.5178108	4123.36118	12.75546	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr2	204137443	chr2:204137443	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr3	1339632	1339633	GC	-	exonic	CNTN6	.	frameshift deletion	CNTN6:NM_001289081:exon6:c.502_503del:p.A168Kfs*19,CNTN6:NM_001289080:exon7:c.718_719del:p.A240Kfs*19,CNTN6:NM_014461:exon7:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349352:exon8:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349353:exon8:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349354:exon8:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349355:exon8:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349350:exon9:c.718_719del:p.A240Kfs*19,CNTN6:NM_001349351:exon9:c.718_719del:p.A240Kfs*19	3.59E-22	0.004010738	0.995989262	.	0.44656	0.13084	-0.918644703	9.807737674	343.14195	3.92764	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	36.72	15	chr3	1339631	chr3:1339631	TGC	T	36.72	PASS	AN=0;DP=15	GT	0/1
chr3	9439598	9439598	G	A	UTR5	SETD5	NM_001292043:c.-36914G>A;NM_001080517:c.-31025G>A;NM_001349451:c.-36914G>A	.	.	0.999999564	4.36E-07	2.82E-18	DISEASE: Mental retardation, autosomal dominant 23 (MRD23) [MIM:615761]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD23 patients manifest moderate to severe intellectual disability with additional variable features of brachycephaly, a low hairline, depressed nasal bridge, prominent high nasal root, tubular nose, upslanting palpebral fissures, long and smooth philtrum, micrognathia, thin upper lip, and crowded teeth. Behavioral problems, including obsessive-compulsive disorder, hand flapping with ritualized behavior, and autism, are prominent features. {ECO:0000269|PubMed:24680889}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.46735	0.10674	-0.791786324	12.59731069	500.45582	4.59199	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr3	9439598	chr3:9439598	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr3	13651139	13651139	C	A	exonic	FBLN2	.	stopgain	FBLN2:NM_001004019:exon4:c.C1545A:p.Y515X,FBLN2:NM_001165035:exon4:c.C1545A:p.Y515X,FBLN2:NM_001998:exon4:c.C1545A:p.Y515X	0.629825153	0.370172306	2.54E-06	.	0.76637	0.22472	-1.091439713	6.988676575	754.76604	5.44846	.	.	.	.	.	.	.	.	.	0.171	0.174	U	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	10.377	0.967	36	0.996	0.730	0.833	0.421	D	c	0.264	0.018	0.142	0.173	0.706	0.609	0	1.54	0.222	0.063	0.142	-1.011	0.022	0.992	0.373	0.341	0.244	6.913	0.234	Anaphylatoxin/fibulin|Growth factor receptor cysteine-rich domain	.	.	0.5	.	43	chr3	13651139	chr3:13651139	C	A	.	PASS	AN=0;DP=43	GT	0/1
chr3	33645746	33645746	C	T	intronic	CLASP2	.	.	.	0.99994836	5.16E-05	1.08E-16	.	0.48367	0.14642	.	.	656.28546	5.13608	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr3	33645746	chr3:33645746	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr3	47452022	47452022	G	A	exonic	PTPN23	.	nonsynonymous SNV	PTPN23:NM_001304482:exon19:c.G2356A:p.V786M,PTPN23:NM_015466:exon20:c.G2734A:p.V912M	0.647596781	0.352403215	3.63E-09	.	0.09755	0.12139	-1.3304325	4.676810569	1113.07486	6.37437	0.115	0.285	T	0.003	0.102	B	0.004	0.093	B	0.956	0.077	N	1	0.090	N	1.01	0.254	L	4.26	0.026	T	-0.02	0.073	N	0.202	0.248	-0.899	0.481	T	0.005	0.017	T	0.007	0.188	T	-0.678	0.046	0.081	0.850	0.151	0.173	0.196	N	c	-1.205	-1.192	0.997	0.356	0.732	0.924	0	0.612	0.167	2.162	0.418	0.079	0.188	0.316	0.252	0.765	0.326	1.504	0.023	.	.	.	0.5	.	94	chr3	47452022	chr3:47452022	G	A	.	PASS	AN=0;DP=94	GT	0/1
chr3	53321295	53321295	C	T	UTR3	DCP1A	NM_001290205:c.*303G>A;NM_001290206:c.*303G>A;NM_001290204:c.*303G>A;NM_018403:c.*303G>A;NM_001290207:c.*303G>A	.	.	0.943913888	0.056077565	8.55E-06	.	0.44145	0.11103	.	.	160.55737	2.76552	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr3	53321295	chr3:53321295	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr3	57335799	57335799	G	A	exonic	DNAH12	.	unknown	UNKNOWN	0.000394166	0.95768566	0.041920174	.	0.40937	0.09978	0.841481379	88.35810333	7404.50475	18.48845	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	75	chr3	57335799	chr3:57335799	G	A	.	PASS	AN=0;DP=75	GT	0/1
chr3	71007068	71007068	G	A	UTR3	FOXP1	NM_001244813:c.*1330C>T;NM_001244814:c.*1330C>T;NM_001244815:c.*1330C>T;NM_001244810:c.*1330C>T;NM_001244816:c.*1330C>T;NM_001244812:c.*1330C>T;NM_001244808:c.*1330C>T;NM_032682:c.*1330C>T;NM_001349344:c.*1330C>T;NM_001349342:c.*1330C>T;NM_001349343:c.*1330C>T;NM_001349338:c.*1330C>T;NM_001349339:c.*1330C>T;NM_001349340:c.*1330C>T;NM_001349341:c.*1330C>T;NM_001349337:c.*1330C>T	.	.	0.999750735	0.000249265	1.47E-11	DISEASE: Note=A chromosomal aberration involving FOXP1 is found in acute lymphoblastic leukemia. Translocation t(9;3)(p13;p14.1) with PAX5.; DISEASE: Mental retardation with language impairment and autistic features (MRLIAF) [MIM:613670]: A developmental disorder characterized by mild to moderate mental retardation, language impairment, and autistic features. Patients show global delay, delayed walking, severely delayed speech development, and behavioral abnormalities, including irritability, hyperactivity, aggression, and stereotypical rigid behaviors. {ECO:0000269|PubMed:20950788}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.57291	0.32628	-0.378346116	28.01368247	60.34446	1.57849	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	57	chr3	71007068	chr3:71007068	G	A	.	PASS	AN=0;DP=57	GT	0/1
chr3	111873836	111873836	A	T	intronic	SLC9C1	.	.	.	7.82E-11	0.992493746	0.007506253	.	0.03558	0.05202	1.631430616	96.06628922	6774.45187	17.48499	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr3	111873836	chr3:111873836	A	T	.	PASS	AN=0;DP=28	GT	0/1
chr3	111873837	111873837	A	T	intronic	SLC9C1	.	.	.	7.82E-11	0.992493746	0.007506253	.	0.03558	0.05202	1.631430616	96.06628922	6774.45187	17.48499	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr3	111873837	chr3:111873837	A	T	.	PASS	AN=0;DP=28	GT	0/1
chr3	124066047	124066047	G	T	exonic	KALRN	.	nonsynonymous SNV	KALRN:NM_001024660:exon10:c.G1699T:p.G567W,KALRN:NM_001322988:exon10:c.G1699T:p.G567W,KALRN:NM_001322989:exon10:c.G1699T:p.G567W,KALRN:NM_001322990:exon10:c.G1699T:p.G567W,KALRN:NM_001322991:exon10:c.G1699T:p.G567W,KALRN:NM_001322992:exon10:c.G1699T:p.G567W,KALRN:NM_003947:exon10:c.G1699T:p.G567W	0.999996915	3.08E-06	5.55E-19	DISEASE: Coronary heart disease 5 (CHDS5) [MIM:608901]: A multifactorial disease characterized by an imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. Decreased capacity of the coronary vessels is often associated with thickening and loss of elasticity of the coronary arteries. {ECO:0000269|PubMed:17357071}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.66718	.	-3.651326374	0.271290399	881.44733	5.78506	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1	0.810	D	2.675	0.786	M	0.79	0.491	T	-6.48	0.944	D	0.957	0.991	-0.026	0.817	T	0.499	0.810	T	0.337	0.919	D	5.508	0.748	26.3	0.997	0.784	0.984	0.824	D	c	0.639	0.686	1.000	0.747	0.633	0.409	0	5.31	0.750	10.003	0.997	1.045	0.669	1.000	0.715	1.000	0.888	19.173	0.935	.	.	.	0.5	.	38	chr3	124066047	chr3:124066047	G	T	.	PASS	AN=0;DP=38	GT	0/1
chr3	129308224	129308224	G	A	exonic	PLXND1	.	synonymous SNV	PLXND1:NM_015103:exon2:c.C1458T:p.F486F	0.999989725	1.03E-05	5.15E-17	.	0.15642	0.1259	-1.306585655	4.883227176	2739.76702	9.86834	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	156	chr3	129308224	chr3:129308224	G	A	.	PASS	AN=0;DP=156	GT	0/1
chr3	142184059	142184059	C	T	exonic	ATR	.	synonymous SNV	ATR:NM_001184:exon41:c.G6921A:p.Q2307Q	0.701297833	0.298702167	5.04E-17	DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal recessive disorder characterized by proportionate dwarfism of prenatal onset associated with low birth weight, growth retardation, severe microcephaly with a bird-headed like appearance, and mental retardation. {ECO:0000269|PubMed:12640452}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) [MIM:614564]: A disease characterized by cutaneous telangiectases in infancy with patchy alopecia over areas of affected skin, thinning of the lateral eyebrows, and mild dental and nail anomalies. Affected individuals are at increased risk of developing oropharyngeal cancer, and other malignancies have been reported as well. {ECO:0000269|PubMed:22341969}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.81267	0.14325	-1.639226005	2.789573013	836.25678	5.6623	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr3	142184059	chr3:142184059	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr3	149233577	149233577	T	-	intergenic	TM4SF4;WWTR1	dist=12396;dist=1439	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	70	chr3	149233576	chr3:149233576	AT	A	39	PASS	AN=2;DP=70	GT	0/1
chr3	186006618	186006618	G	C	exonic	DGKG	.	nonsynonymous SNV	DGKG:NM_001080744:exon6:c.C425G:p.T142S,DGKG:NM_001080745:exon6:c.C425G:p.T142S,DGKG:NM_001346:exon6:c.C425G:p.T142S	5.44E-06	0.99850148	0.001493082	.	0.45176	0.18992	-1.524862616	3.42061807	110.98235	2.29646	0.814	0.033	T	0.002	0.090	B	0.006	0.133	B	0.914	0.085	N	1	0.090	P	0.695	0.181	N	1.0	0.414	T	0.04	0.065	N	0.057	0.040	-0.922	0.453	T	0.000	0.000	T	.	.	.	-1.570	0.015	0.002	0.428	0.032	0.063	0.122	N	c	-1.255	-1.199	0.996	0.343	0.487	0.133	0	2.16	0.265	1.920	0.394	-0.752	0.034	0.802	0.295	0.000	0.016	5.379	0.154	Diacylglycerol kinase type I, N-terminal	.	.	0.5	54	15	chr3	186006618	chr3:186006618	G	C	54	PASS	AN=2;DP=15	GT	0/1
chr3	187455476	187455476	C	T	intronic	BCL6	.	.	.	0.982525139	0.017474389	4.71E-07	DISEASE: Note=Chromosomal aberrations involving BCL6 are a cause of B-cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell lymphoma and follicular lymphoma. Approximately 40% of diffuse large B-cell lymphomas and 5 to 10% of follicular lymphomas are associated with chromosomal translocations that deregulate expression of BCL6 by juxtaposing heterologous promoters to the BCL6 coding domain. Translocation t(3;14)(q27;q32). Translocation t(3;22)(q27;q11) with immunoglobulin gene regions. Translocation t(3;7)(q27;p12) with IKZF1 gene 5'non-coding region. Translocation t(3;6)(q27;p21) with Histone H4. Translocation t(3;16)(q27;p11) with IL21R. Translocation t(3;13)(q27;q14) with LCP1.; DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of a form of B-cell leukemia. Translocation t(3;11)(q27;q23) with POU2AF1/OBF1.; DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of lymphoma. Translocation t(3;4)(q27;p11) with ARHH/TTF.; 	0.3437	0.5169	-0.464712395	23.5727766	1225.27484	6.61711	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	142	chr3	187455476	chr3:187455476	C	T	.	PASS	AN=0;DP=142	GT	0/1
chr4	337623	337623	A	T	exonic	ZNF141	.	nonsynonymous SNV	ZNF141:NM_001348278:exon2:c.A56T:p.K19I,ZNF141:NM_001348279:exon2:c.A56T:p.K19I,ZNF141:NM_001348280:exon2:c.A56T:p.K19I,ZNF141:NM_003441:exon2:c.A56T:p.K19I	0.161888983	0.82300848	0.015102537	.	0.39436	0.16446	0.795569043	87.49115357	156.94519	2.73623	0.001	0.784	D	0.971	0.689	D	0.9	0.644	P	.	.	.	1	0.090	N	1.76	0.459	L	4.56	0.020	T	-4.42	0.838	D	0.287	0.349	-0.968	0.375	T	0.015	0.058	T	0.001	0.019	T	2.620	0.376	20.3	0.991	0.520	0.002	0.010	N	c	-0.363	-0.566	0.002	0.089	0.732	0.924	0	-0.113	0.128	-2.009	0.015	-0.510	0.051	0.000	0.063	0.858	0.358	3.763	0.081	Krueppel-associated box	.	.	0.5	.	25	chr4	337623	chr4:337623	A	T	.	PASS	AN=0;DP=25	GT	0/1
chr4	8207201	8207201	G	T	intronic	SH3TC1	.	.	.	1.08E-27	1.60E-05	0.999983988	.	0.06743	.	1.017812819	90.87638594	4345.64439	13.13144	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	30	chr4	8207201	chr4:8207201	G	T	.	PASS	AN=0;DP=30	GT	0/1
chr4	9710546	9710546	G	A	intergenic	MIR548I2;DRD5	dist=152609;dist=72712	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	49	chr4	9710546	chr4:9710546	G	A	.	PASS	AN=0;DP=49	GT	0/1
chr4	15982007	15982101	AAAATGACCCCCACGTCTGTGGAAGCCCACATACTTACTCATCGTACACGTCCTCCGAATCCATTCGACGATAGTACTTAGCCAGTTTTACCGCA	-	exonic	PROM1	.	nonframeshift deletion	PROM1:NM_001145851:exon22:c.2406_2462del:p.A803_D821del,PROM1:NM_001145852:exon22:c.2406_2462del:p.A803_D821del,PROM1:NM_001145847:exon23:c.2406_2462del:p.A803_D821del,PROM1:NM_001145848:exon23:c.2406_2462del:p.A803_D821del,PROM1:NM_001145849:exon23:c.2433_2489del:p.A812_D830del,PROM1:NM_001145850:exon23:c.2433_2489del:p.A812_D830del,PROM1:NM_006017:exon23:c.2433_2489del:p.A812_D830del	7.17E-17	0.027832798	0.972167202	DISEASE: Retinitis pigmentosa 41 (RP41) [MIM:612095]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10587575, ECO:0000269|PubMed:17605048}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy 12 (CORD12) [MIM:612657]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Stargardt disease 4 (STGD4) [MIM:603786]: A common hereditary macular degeneration. It is characterized by decreased central vision, atrophy of the macula and underlying retinal pigment epithelium, and frequent presence of prominent flecks in the posterior pole of the retina. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinal macular dystrophy 2 (MCDR2) [MIM:608051]: A bull's-eye macular dystrophy characterized by bilateral annular atrophy of retinal pigment epithelium at the macula. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31674	0.31496	-1.368693559	4.482189196	96.86296	2.12686	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	16.47	81	chr4	15982006	chr4:15982006	GAAAATGACCCCCACGTCTGTGGAAGCCCACATACTTACTCATCGTACACGTCCTCCGAATCCATTCGACGATAGTACTTAGCCAGTTTTACCGCA	G	16.47	PASS	AN=0;DP=81	GT	0/1
chr4	41631761	41631772	GTTTCCCCCCCA	-	intronic	LIMCH1	.	.	.	0.999638379	0.000361621	3.01E-13	.	0.22998	0.08738	0.387604191	75.69591885	5384.20261	15.13173	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	39	36	chr4	41631760	chr4:41631760	TGTTTCCCCCCCA	T	39	PASS	AN=2;DP=36	GT	0/1
chr4	71588258	71588258	C	G	UTR5	RUFY3	NM_014961:c.-33C>G;NM_001291994:c.-33C>G;NM_001037442:c.-33C>G	.	.	0.980976379	0.019023598	2.38E-08	.	0.86149	0.084	-0.844966979	11.1759849	66.52798	1.68028	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	32	chr4	71588258	chr4:71588258	C	G	65	PASS	AN=2;DP=32	GT	0/1
chr4	126411032	126411032	C	A	intronic	FAT4	.	.	.	0.999999998	1.64E-09	5.84E-27	DISEASE: Van Maldergem syndrome 2 (VMLDS2) [MIM:615546]: An autosomal recessive disorder characterized by intellectual disability, typical craniofacial features, auditory malformations resulting in hearing loss, and skeletal and limb malformations. Some patients have renal hypoplasia. Brain MRI typically shows periventricular nodular heterotopia. {ECO:0000269|PubMed:24056717}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) [MIM:616006]: A form of Hennekam lymphangiectasia-lymphedema syndrome, a generalized lymph-vessels dysplasia characterized by intestinal lymphangiectasia with severe lymphedema of the limbs, genitalia and face. In addition, affected individuals have unusual facies and severe mental retardation. HKLLS2 individuals have lymphangiectasia variably affecting the gut, pericardium, lungs, kidneys, and genitalia. Other features include camptodactyly and rare syndactyly. {ECO:0000269|PubMed:24913602}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.2094	0.10056	-0.502828893	21.81528662	13346.97344	24.85144	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	36	chr4	126411032	chr4:126411032	C	A	.	PASS	AN=0;DP=36	GT	0/1
chr4	151560855	151560856	AC	-	intronic	LRBA	.	.	.	0.044229437	0.955770563	1.54E-17	DISEASE: Immunodeficiency, common variable, 8, with autoimmunity (CVID8) [MIM:614700]: An autosomal recessive immunologic disorder associated with defective B-cell differentiation and decreased or absent antibody production. Affected individuals have early- childhood onset of recurrent infections, particularly respiratory infections, and also develop variable autoimmune disorders, including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and inflammatory bowel disease. {ECO:0000269|PubMed:22608502}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31593	.	-2.513092117	0.925925926	4753.32179	13.94798	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	88	104	chr4	151560854	chr4:151560854	GAC	G	88	PASS	AN=2;DP=104	GT	0/1
chr5	666067	666067	C	T	intronic	TPPP	.	.	.	0.447860539	0.523687832	0.028451629	.	0.32775	0.16177	-0.315847836	31.68789809	36.35113	1.08938	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	96	chr5	666067	chr5:666067	C	T	.	PASS	AN=0;DP=96	GT	0/1
chr5	36876996	36876996	G	T	UTR5	NIPBL	NM_015384:c.-76803G>T;NM_133433:c.-76803G>T	.	.	1	9.20E-18	1.38E-43	DISEASE: Cornelia de Lange syndrome 1 (CDLS1) [MIM:122470]: A form of Cornelia de Lange syndrome, a clinically heterogeneous developmental disorder associated with malformations affecting multiple systems. Characterized by facial dysmorphisms, abnormal hands and feet, growth delay, cognitive retardation, hirsutism, gastroesophageal dysfunction and cardiac, ophthalmologic and genitourinary anomalies. {ECO:0000269|PubMed:15146185, ECO:0000269|PubMed:15146186, ECO:0000269|PubMed:15318302, ECO:0000269|PubMed:20124326, ECO:0000269|PubMed:20358602, ECO:0000269|PubMed:21934712, ECO:0000269|PubMed:23254390, ECO:0000269|PubMed:25447906}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.94334	0.10487	-2.44943873	1.014390186	759.33568	5.46172	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	62	chr5	36876996	chr5:36876996	G	T	.	PASS	AN=0;DP=62	GT	0/1
chr5	43122286	43122286	A	T	intronic	ZNF131	.	.	.	0.999460222	0.000539776	2.35E-09	.	0.28126	0.10787	0.128714042	63.19886766	86.63819	1.98849	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	99	chr5	43122286	chr5:43122286	A	T	.	PASS	AN=0;DP=99	GT	0/1
chr5	54468512	54468512	A	G	intronic	CDC20B	.	.	.	1.44E-11	0.098587056	0.901412944	.	0.13927	0.08133	0.933309256	89.82661005	1377.34214	6.95718	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr5	54468512	chr5:54468512	A	G	.	PASS	AN=0;DP=39	GT	0/1
chr5	78610548	78610548	G	A	exonic	JMY	.	nonsynonymous SNV	JMY:NM_152405:exon9:c.G2533A:p.E845K	0.999722637	0.000277363	1.90E-11	.	.	.	0.88921411	89.24274593	2992.00625	10.37986	0.01	0.564	D	0.465	0.346	P	0.124	0.310	B	0.001	0.432	D	0.763	0.340	D	1.255	0.319	L	1.59	0.288	T	-0.34	0.127	N	0.138	0.185	-1.058	0.123	T	0.048	0.204	T	0.007	0.194	T	2.966	0.417	22.1	0.997	0.838	0.940	0.597	D	c	-0.106	-0.003	0.129	0.171	0.563	0.310	0	4.91	0.638	1.969	0.399	0.953	0.551	0.107	0.227	0.992	0.562	8.579	0.326	.	.	.	0.5	.	47	chr5	78610548	chr5:78610548	G	A	.	PASS	AN=0;DP=47	GT	0/1
chr5	98217050	98217050	G	A	exonic	CHD1	.	nonsynonymous SNV	CHD1:NM_001270:exon20:c.C2897T:p.S966L	0.999999999	6.37E-10	3.50E-25	.	0.88289	0.17305	-0.813834387	12.05472989	1749.76488	7.72416	0.002	0.721	D	0.439	0.340	B	0.165	0.334	B	0.012	0.292	U	1	0.810	D	0.935	0.237	L	-3.74	0.955	D	-3.68	0.703	D	0.56	0.594	0.506	0.906	D	0.722	0.905	D	0.204	0.869	D	6.949	0.934	33	0.998	0.922	0.993	0.945	D	c	0.277	0.442	1.000	0.747	0.732	0.924	0	5.13	0.696	10.003	0.997	0.902	0.416	1.000	0.715	0.996	0.625	18.945	0.926	P-loop containing nucleoside triphosphate hydrolase	.	.	0.5	.	47	chr5	98217050	chr5:98217050	G	A	.	PASS	AN=0;DP=47	GT	0/1
chr5	99403740	99403740	T	C	intergenic	LINC02113;LOC100133050	dist=490082;dist=311469	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	131	331	chr5	99403740	chr5:99403740	T	C	131	PASS	AN=2;DP=331	GT	0/1
chr5	122714059	122714059	C	T	exonic	CEP120	.	nonsynonymous SNV	CEP120:NM_001166226:exon15:c.G2089A:p.E697K,CEP120:NM_153223:exon16:c.G2167A:p.E723K	4.34E-11	0.982961028	0.017038972	DISEASE: Short-rib thoracic dysplasia 13 with or without polydactyly (SRTD13) [MIM:616300]: A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. {ECO:0000269|PubMed:25361962}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.20235	.	0.007353605	54.12243454	6832.03941	17.5857	0.005	0.632	D	1.0	0.899	D	0.994	0.807	D	0.000	0.843	D	1.000	0.548	D	2.58	0.756	M	0.25	0.595	T	-2.77	0.598	D	0.92	0.911	-0.280	0.756	T	0.429	0.772	T	0.065	0.696	D	6.733	0.919	32	0.999	0.986	0.992	0.931	D	c	0.819	0.798	1.000	0.747	0.732	0.924	0	5.8	0.921	6.636	0.740	0.932	0.445	1.000	0.715	0.892	0.376	20.056	0.976	.	.	.	0.5	.	33	chr5	122714059	chr5:122714059	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr5	131940703	131940703	C	T	intronic	RAD50	.	.	.	3.45E-15	0.992354993	0.007645007	DISEASE: Nijmegen breakage syndrome-like disorder (NBSLD) [MIM:613078]: A disorder similar to Nijmegen breakage syndrome and characterized by chromosomal instability, radiation sensitivity, microcephaly, growth retardation, short stature and bird-like face. Immunodeficiency is absent. {ECO:0000269|PubMed:19409520}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75384	0.58646	-0.501537595	21.83887709	175.25604	2.87907	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	22	chr5	131940703	chr5:131940703	C	T	.	PASS	AN=0;DP=22	GT	0/1
chr5	136476334	136476334	G	A	exonic	SPOCK1	.	synonymous SNV	SPOCK1:NM_004598:exon4:c.C282T:p.H94H	0.320886445	0.678398903	0.000714652	.	0.28758	0.20627	-0.490397599	22.50530786	83.60687	1.94449	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr5	136476334	chr5:136476334	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr5	137909423	137909424	AT	-	intronic	HSPA9	.	.	.	0.981119322	0.018880654	2.34E-08	.	0.62414	0.7341	-0.846787714	11.05803255	21.59412	0.72579	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	104	chr5	137909422	chr5:137909422	GAT	G	72	PASS	AN=2;DP=104	GT	0/1
chr5	141312733	141312733	G	A	intronic	KIAA0141	.	.	.	3.06E-10	0.281915895	0.718084105	.	0.04807	.	0.69078985	85.23826374	2730.37291	9.84899	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	23	chr5	141312733	chr5:141312733	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr5	149599293	149599293	T	C	UTR3	CAMK2A	NM_171825:c.*2980A>G;NM_015981:c.*2980A>G	.	.	0.998004221	0.001995777	2.34E-09	.	0.6957	0.38769	-0.538132194	20.26421326	1.83486	0.0579	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr5	149599293	chr5:149599293	T	C	.	PASS	AN=0;DP=46	GT	0/1
chr5	151180401	151180401	G	T	exonic	G3BP1	.	stopgain	G3BP1:NM_005754:exon11:c.G1165T:p.E389X,G3BP1:NM_198395:exon11:c.G1165T:p.E389X	0.988390764	0.011609063	1.73E-07	.	0.91724	0.16278	-0.361761279	28.6329323	35.68074	1.07372	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.690	0.997	47	0.997	0.833	0.994	0.953	D	c	1.242	1.102	1.000	0.747	0.719	0.830	0	5.54	0.828	9.219	0.943	1.048	0.713	1.000	0.715	1.000	0.888	19.502	0.951	Nucleotide-binding alpha-beta plait domain|RNA recognition motif domain	.	.	0.5	.	30	chr5	151180401	chr5:151180401	G	T	.	PASS	AN=0;DP=30	GT	0/1
chr5	159766443	159766443	T	C	intergenic	CCNJL;C1QTNF2	dist=26836;dist=8332	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	90	chr5	159766443	chr5:159766443	T	C	62	PASS	AN=2;DP=90	GT	0/1
chr5	168044019	168044019	C	-	intergenic	PANK3;SLIT3	dist=37405;dist=44719	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	211	chr5	168044018	chr5:168044018	GC	G	84	PASS	AN=2;DP=211	GT	0/1
chr5	175824557	175824557	C	G	intronic	CLTB	.	.	.	0.11549246	0.85740865	0.02709889	.	0.42524	0.24613	-0.229483771	36.86010852	6.86616	0.25469	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	96	426	chr5	175824557	chr5:175824557	C	G	96	PASS	AN=2;DP=426	GT	0/1
chr5	176636551	176636551	A	-	intronic	NSD1	.	.	.	0.999999999	8.21E-10	2.66E-26	DISEASE: Beckwith-Wiedemann syndrome (BWS) [MIM:130650]: A disorder characterized by anterior abdominal wall defects including exomphalos (omphalocele), pre- and postnatal overgrowth, and macroglossia. Additional less frequent complications include specific developmental defects and a predisposition to embryonal tumors. {ECO:0000269|PubMed:14997421}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving NSD1 is found in childhood acute myeloid leukemia. Translocation t(5;11)(q35;p15.5) with NUP98.; DISEASE: Note=A chromosomal aberration involving NSD1 is found in an adult form of myelodysplastic syndrome (MDS). Insertion of NUP98 into NSD1 generates a NUP98-NSD1 fusion product. {ECO:0000269|PubMed:15382262}.; 	0.66088	0.2415	-1.552781294	3.237791932	2326.46017	8.93558	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	18.65	70	chr5	176636550	chr5:176636550	TA	T	18.65	PASS	AN=0;DP=70	GT	0/1
chr5	176883771	176883771	T	A	UTR3	DBN1	NM_080881:c.*663A>T;NM_004395:c.*663A>T	.	.	0.962685619	0.037313758	6.23E-07	.	0.24114	0.19461	-0.086288664	47.11606511	845.8418	5.68937	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	79	chr5	176883771	chr5:176883771	T	A	.	PASS	AN=0;DP=79	GT	0/1
chr6	10419579	10419579	C	T	intronic	TFAP2A	.	.	.	0.987223276	0.012771396	5.33E-06	DISEASE: Branchiooculofacial syndrome (BOFS) [MIM:113620]: A syndrome characterized by growth retardation, bilateral branchial sinus defects with hemangiomatous, scarred skin, cleft lip with or without cleft palate, pseudocleft of the upper lip, nasolacrimal duct obstruction, low set ears with posterior rotation, a malformed, asymmetrical nose with a broad bridge and flattened tip, conductive or sensorineural deafness, ocular and renal anomalies. {ECO:0000269|PubMed:18423521}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.96726	0.95367	-0.427900189	25.14744043	13.97787	0.50725	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	33	chr6	10419579	chr6:10419579	C	T	58	PASS	AN=2;DP=33	GT	0/1
chr6	27115555	27115555	C	T	upstream;downstream	HIST1H2BK;HIST1H2AH;MIR3143	dist=918;dist=88	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	56	chr6	27115555	chr6:27115555	C	T	.	PASS	AN=0;DP=56	GT	0/1
chr6	33646313	33646313	C	T	exonic	ITPR3	.	nonsynonymous SNV	ITPR3:NM_002224:exon29:c.C3764T:p.T1255M	4.98E-12	0.999999998	1.88E-09	.	0.69563	.	-4.091558817	0.165133286	605.21718	4.97953	0.004	0.654	D	1.0	0.899	D	0.99	0.774	D	0.000	0.843	D	1.000	0.537	D	2.305	0.662	M	-2.5	0.892	D	-3.63	0.697	D	0.35	0.576	0.675	0.929	D	0.790	0.929	D	0.148	0.831	D	6.600	0.907	31	0.999	0.982	0.942	0.601	D	c	0.638	0.605	1.000	0.747	0.732	0.924	0	5.65	0.868	3.290	0.512	0.852	0.362	0.998	0.411	0.863	0.360	19.726	0.961	RIH (RyR and IP3R Homology) domain	.	.	0.5	.	73	chr6	33646313	chr6:33646313	C	T	.	PASS	AN=0;DP=73	GT	0/1
chr6	34212805	34212805	C	T	UTR3	HMGA1	NM_001319081:c.*144C>T;NM_001319080:c.*144C>T;NM_001319082:c.*144C>T;NM_002131:c.*144C>T;NM_145899:c.*144C>T;NM_001319079:c.*144C>T;NM_001319078:c.*144C>T;NM_001319077:c.*144C>T;NM_145903:c.*144C>T;NM_145902:c.*144C>T;NM_145901:c.*144C>T;NM_145905:c.*144C>T	.	.	0.724299774	0.262579444	0.013120782	DISEASE: Note=A chromosomal aberration involving HMGA1 is found in pulmonary chondroid hamartoma. Translocation t(6;14)(p21;q23-24) with RAD51B. {ECO:0000269|PubMed:11978964}.; 	0.99432	0.53499	-0.053113545	49.38664779	74.66102	1.80667	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	126	chr6	34212805	chr6:34212805	C	T	.	PASS	AN=0;DP=126	GT	0/1
chr6	51930801	51930801	C	T	exonic	PKHD1	.	nonsynonymous SNV	PKHD1:NM_138694:exon12:c.G853A:p.D285N,PKHD1:NM_170724:exon12:c.G853A:p.D285N	2.89E-23	1	2.32E-11	.	0.08201	0.25544	0.37824847	75.51309271	3737.47294	11.94762	0.087	0.357	T	0.787	0.438	P	0.447	0.484	P	0.001	0.424	D	0.746	0.297	N	1.555	0.395	L	-1.06	0.768	T	-3.02	0.660	D	0.061	0.045	-0.665	0.621	T	0.267	0.639	T	0.069	0.708	D	6.385	0.882	29.5	0.999	0.939	0.814	0.405	D	c	0.320	0.416	1.000	0.747	0.497	0.185	0	5.95	0.964	2.001	0.402	0.065	0.171	1.000	0.715	0.714	0.313	14.926	0.704	IPT domain|Immunoglobulin E-set|Immunoglobulin-like fold	.	.	0.5	.	21	chr6	51930801	chr6:51930801	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr6	72951999	72951999	-	T	intronic	RIMS1	.	.	.	0.029211449	0.970788551	5.09E-11	DISEASE: Cone-rod dystrophy 7 (CORD7) [MIM:603649]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. {ECO:0000269|PubMed:12659814}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; 	0.52106	0.15134	-1.543300564	3.320358575	440.01281	4.37079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	21.55	26	chr6	72951999	chr6:72951999	C	CT	21.55	PASS	AN=0;DP=26	GT	0/1
chr6	134212833	134212833	C	T	intronic	TCF21	.	.	.	0.805369944	0.189537108	0.005092948	.	0.50048	0.24689	0.25917371	70.05779665	477.84739	4.51344	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	353	chr6	134212833	chr6:134212833	C	T	.	PASS	AN=0;DP=353	GT	0/1
chr6	149842224	149842224	C	A	exonic	PPIL4	.	synonymous SNV	PPIL4:NM_139126:exon10:c.G954T:p.S318S	1.68E-05	0.992867371	0.00711582	.	0.28458	0.1178	-0.159704656	41.90846898	84.52811	1.95737	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	42	chr6	149842224	chr6:149842224	C	A	.	PASS	AN=0;DP=42	GT	0/1
chr6	163991862	163991862	C	T	UTR3	QKI	NM_001301085:c.*120C>T;NM_206855:c.*7085C>T;NM_206854:c.*6120C>T;NM_206853:c.*4859C>T;NM_006775:c.*120C>T	.	.	0.963163356	0.036821914	1.47E-05	.	0.28593	0.19768	-0.229483771	36.86010852	6.7048	0.2474	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	32	chr6	163991862	chr6:163991862	C	T	.	PASS	AN=0;DP=32	GT	0/1
chr7	975047	975047	G	A	exonic	ADAP1	.	synonymous SNV	ADAP1:NM_001284308:exon2:c.C210T:p.S70S,ADAP1:NM_006869:exon2:c.C177T:p.S59S	0.657926854	0.341835895	0.000237251	.	0.17754	0.12827	-0.933156985	9.54824251	48.02044	1.34684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr7	975047	chr7:975047	G	A	.	PASS	AN=0;DP=44	GT	0/1
chr7	1538608	1538608	C	T	intronic	INTS1	.	.	.	0.224121375	0.775878625	1.91E-10	.	0.15585	.	-5.050633482	0.070771408	422.05224	4.29253	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	37	chr7	1538608	chr7:1538608	C	T	.	PASS	AN=0;DP=37	GT	0/1
chr7	38423310	38423311	GT	-	UTR3	AMPH	NM_139316:c.*1109_*1108delAC;NM_001635:c.*1109_*1108delAC	.	.	0.032266566	0.96771785	1.56E-05	.	0.23196	0.19053	0.225995239	68.51851852	678.4813	5.20472	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	15	chr7	38423309	chr7:38423309	GGT	G	42	PASS	AN=2;DP=15	GT	0/1
chr7	55259515	55259515	T	G	exonic	EGFR	.	nonsynonymous SNV	EGFR:NM_001346941:exon15:c.T1772G:p.L591R,EGFR:NM_001346897:exon20:c.T2438G:p.L813R,EGFR:NM_001346899:exon20:c.T2438G:p.L813R,EGFR:NM_001346898:exon21:c.T2573G:p.L858R,EGFR:NM_001346900:exon21:c.T2414G:p.L805R,EGFR:NM_005228:exon21:c.T2573G:p.L858R	0.99866453	0.00133547	2.97E-13	DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) [MIM:616069]: A disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99968	0.98895	-2.160861741	1.439018636	119.9504	2.38669	0.0	0.912	D	0.999	0.899	D	0.956	0.916	D	0.000	0.504	D	1.000	0.810	D	3.65	0.943	H	-2.83	0.913	D	-5.23	0.839	D	0.989	0.993	0.987	0.970	D	0.881	0.960	D	0.698	0.975	D	6.930	0.933	33	0.998	0.896	0.981	0.798	D	c	0.927	0.868	1.000	0.747	0.741	0.978	0	5.71	0.890	7.960	0.873	1.061	0.807	1.000	0.715	1.000	0.888	14.811	0.695	Protein kinase domain|Protein kinase-like domain|Serine-threonine/tyrosine-protein kinase catalytic domain|Tyrosine-protein kinase, catalytic domain	.	.	0.5	81	46	chr7	55259515	chr7:55259515	T	G	81	PASS	AN=2;DP=46	GT	1/0
chr7	56146228	56146242	GGGGCCTTGTAGCTG	-	intronic	SUMF2	.	.	.	5.53E-05	0.883050597	0.11689414	.	0.07185	0.68732	0.420771676	77.15852795	226.86098	3.25511	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	12.69	44	chr7	56146227	chr7:56146227	CGGGGCCTTGTAGCTG	C	12.69	PASS	AN=0;DP=44	GT	0/1
chr7	70229796	70229796	C	T	exonic	AUTS2	.	nonsynonymous SNV	AUTS2:NM_001127231:exon8:c.C1273T:p.H425Y,AUTS2:NM_015570:exon8:c.C1273T:p.H425Y	0.996187482	0.003812518	9.39E-11	.	0.83083	0.1075	-1.967739992	1.816466148	320.02805	3.80007	0.008	0.721	D	0.347	0.318	B	0.085	0.279	B	0.000	0.843	D	1.000	0.588	D	1.875	0.501	L	1.29	0.358	T	-2.63	0.597	D	0.321	0.385	-1.066	0.102	T	0.094	0.357	T	0.021	0.434	T	4.373	0.585	24.1	0.997	0.793	0.826	0.415	D	c	0.225	0.362	1.000	0.747	0.635	0.413	0	5.45	0.796	5.331	0.655	0.919	0.430	1.000	0.715	1.000	0.888	18.297	0.900	.	.	.	0.5	.	40	chr7	70229796	chr7:70229796	C	T	.	PASS	AN=0;DP=40	GT	0/1
chr7	70229870	70229870	G	A	exonic	AUTS2	.	synonymous SNV	AUTS2:NM_001127231:exon8:c.G1347A:p.Q449Q,AUTS2:NM_015570:exon8:c.G1347A:p.Q449Q	0.996187482	0.003812518	9.39E-11	.	0.83083	0.1075	-1.967739992	1.816466148	320.02805	3.80007	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	43	chr7	70229870	chr7:70229870	G	A	.	PASS	AN=0;DP=43	GT	0/1
chr7	77006605	77006605	T	C	exonic	GSAP	.	nonsynonymous SNV	GSAP:NM_001350900:exon7:c.A34G:p.K12E,GSAP:NM_001350901:exon7:c.A34G:p.K12E,GSAP:NM_001350898:exon8:c.A622G:p.K208E,GSAP:NM_001350896:exon9:c.A679G:p.K227E,GSAP:NM_001350897:exon9:c.A679G:p.K227E,GSAP:NM_001350899:exon9:c.A679G:p.K227E,GSAP:NM_017439:exon9:c.A679G:p.K227E	3.60E-16	0.241435267	0.758564733	.	.	.	0.268267497	70.64166077	2346.20682	8.97223	0.048	0.400	D	0.023	0.176	B	0.021	0.181	B	0.066	0.218	U	0.752	0.296	N	1.81	0.478	L	1.92	0.231	T	-2.0	0.461	N	0.317	0.378	-1.087	0.060	T	0.061	0.254	T	0.006	0.156	T	1.735	0.270	14.61	0.996	0.747	0.820	0.410	D	c	-0.232	-0.145	0.078	0.158	0.651	0.465	0	2.72	0.310	1.798	0.382	0.894	0.410	0.980	0.350	0.995	0.604	7.485	0.264	.	.	.	0.5	74	140	chr7	77006605	chr7:77006605	T	C	74	PASS	AN=2;DP=140	GT	0/1
chr7	82764286	82764286	G	T	exonic	PCLO	.	synonymous SNV	PCLO:NM_014510:exon3:c.C2580A:p.T860T,PCLO:NM_033026:exon3:c.C2580A:p.T860T	1	1.11E-11	1.03E-35	DISEASE: Pontocerebellar hypoplasia 3 (PCH3) [MIM:608027]: A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum. Brain MRI shows an abnormally small cerebellum and brainstem, decreased cerebral white matter, and a thin corpus callosum. PCH3 features include seizures, short stature, optic atrophy, progressive microcephaly, severe developmental delay. {ECO:0000269|PubMed:25832664}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.20691	0.08509	-0.175308288	40.56970984	9296.23295	20.89927	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	78	chr7	82764286	chr7:82764286	G	T	58	PASS	AN=2;DP=78	GT	0/1
chr7	99916287	99916287	C	T	intronic	SPDYE3	.	.	.	0.825434138	0.173760887	0.000804975	.	.	.	.	.	7.34499	0.27357	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	61	chr7	99916287	chr7:99916287	C	T	.	PASS	AN=0;DP=61	GT	0/1
chr7	100202013	100202013	C	T	intronic	PCOLCE	.	.	.	0.500664878	0.498454987	0.000880135	.	0.75819	0.14881	-0.134019284	43.90776126	423.68346	4.2979	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	153	chr7	100202013	chr7:100202013	C	T	.	PASS	AN=0;DP=153	GT	0/1
chr7	128033754	128033754	C	G	intronic	IMPDH1	.	.	.	0.005811859	0.993226508	0.000961634	DISEASE: Retinitis pigmentosa 10 (RP10) [MIM:180105]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:11875049, ECO:0000269|PubMed:11875050, ECO:0000269|PubMed:16384941}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leber congenital amaurosis 11 (LCA11) [MIM:613837]: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus. {ECO:0000269|PubMed:16384941}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.69586	0.09849	-0.244249595	36.17008728	74.88549	1.81072	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	93	602	chr7	128033754	chr7:128033754	C	G	93	PASS	AN=2;DP=602	GT	0/1
chr7	130080672	130080672	G	A	intronic	CEP41	.	.	.	0.000125629	0.956230668	0.043643703	DISEASE: Joubert syndrome 15 (JBTS15) [MIM:614464]: An autosomal recessive disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis and polydactyly. {ECO:0000269|PubMed:22246503}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Genetic variations in CEP41 may be associated with susceptibility to autism (PubMed:21438139). {ECO:0000269|PubMed:21438139}.; 	0.35352	0.12266	0.551232944	81.48148148	110.55518	2.28931	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	52	chr7	130080672	chr7:130080672	G	A	.	PASS	AN=0;DP=52	GT	0/1
chr7	130288699	130288699	C	-	intronic	COPG2	.	.	.	0.056037357	0.925314655	0.018647988	.	0.54002	.	.	.	27.4635	0.88482	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	85	chr7	130288698	chr7:130288698	GC	G	75	PASS	AN=2;DP=85	GT	0/1
chr7	149528234	149528234	G	A	exonic	SSPO	.	synonymous SNV	SSPO:NM_198455:exon108:c.G15150A:p.S5050S	.	.	.	.	0.20432	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	53	chr7	149528234	chr7:149528234	G	A	.	PASS	AN=0;DP=53	GT	0/1
chr7	150674901	150674901	C	T	intronic	KCNH2	.	.	.	0.996051302	0.003948686	1.23E-08	DISEASE: Long QT syndrome 2 (LQT2) [MIM:613688]: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. Deafness is often associated with long QT syndrome type 2. {ECO:0000269|PubMed:10086971, ECO:0000269|PubMed:10187793, ECO:0000269|PubMed:10220144, ECO:0000269|PubMed:10517660, ECO:0000269|PubMed:10735633, ECO:0000269|PubMed:10862094, ECO:0000269|PubMed:10973849, ECO:0000269|PubMed:11170080, ECO:0000269|PubMed:12062363, ECO:0000269|PubMed:12354768, ECO:0000269|PubMed:12442276, ECO:0000269|PubMed:12621127, ECO:0000269|PubMed:15051636, ECO:0000269|PubMed:15840476, ECO:0000269|PubMed:16414944, ECO:0000269|PubMed:16922724, ECO:0000269|PubMed:19716085, ECO:0000269|PubMed:22314138, ECO:0000269|PubMed:7889573, ECO:0000269|PubMed:8635257, ECO:0000269|PubMed:8877771, ECO:0000269|PubMed:8914737, ECO:0000269|PubMed:9024139, ECO:0000269|PubMed:9452080, ECO:0000269|PubMed:9544837, ECO:0000269|PubMed:9600240, ECO:0000269|PubMed:9693036}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Short QT syndrome 1 (SQT1) [MIM:609620]: A heart disorder characterized by idiopathic persistently and uniformly short QT interval on ECG in the absence of structural heart disease in affected individuals. It causes syncope and sudden death. {ECO:0000269|PubMed:14676148, ECO:0000269|PubMed:15828882}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.70537	0.29759	-1.460519861	3.809860816	1151.75419	6.46689	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	75	chr7	150674901	chr7:150674901	C	T	58	PASS	AN=2;DP=75	GT	0/1
chr8	25265493	25265493	C	A	intronic	DOCK5	.	.	.	0.001342686	0.998657314	3.76E-11	.	.	0.14957	-2.350524415	1.150035386	3159.36883	10.70955	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr8	25265493	chr8:25265493	C	A	.	PASS	AN=0;DP=21	GT	0/1
chr8	52733079	52733079	A	C	exonic	PCMTD1	.	nonsynonymous SNV	PCMTD1:NM_001286782:exon4:c.T678G:p.S226R,PCMTD1:NM_001286783:exon6:c.T378G:p.S126R,PCMTD1:NM_052937:exon6:c.T906G:p.S302R	2.56E-06	0.503470629	0.496526814	.	.	0.10723	0.169169615	65.33380514	3481.72932	11.35685	0.069	0.496	T	0.999	0.764	D	0.994	0.807	D	0.000	0.629	N	1.000	0.588	D	1.955	0.530	M	0.98	0.421	T	-0.9	0.468	N	0.411	0.776	-0.920	0.455	T	0.174	0.518	T	.	.	.	1.490	0.241	13.26	0.998	0.850	0.846	0.434	D	c	0.047	0.054	0.982	0.303	0.707	0.730	0	0.773	0.176	1.452	0.345	0.237	0.263	1.000	0.715	0.999	0.750	6.433	0.209	S-adenosyl-L-methionine-dependent methyltransferase	.	.	0.5	50	11	chr8	52733079	chr8:52733079	A	C	50	PASS	AN=2;DP=11	GT	0/1
chr8	61178677	61178677	T	-	intronic	CA8	.	.	.	0.783927467	0.215775275	0.000297259	DISEASE: Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 3 (CMARQ3) [MIM:613227]: A congenital cerebellar ataxia associated with dysarthia, quadrupedal gait and mental retardation. {ECO:0000269|PubMed:19461874}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.43521	0.13588	-0.007201372	53.19061099	79.99996	1.89165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	14	chr8	61178676	chr8:61178676	CT	C	43	PASS	AN=2;DP=14	GT	0/1
chr8	92971272	92971272	G	A	UTR3	RUNX1T1	NM_001198626:c.*1198C>T;NM_001198625:c.*1198C>T;NM_001198633:c.*1198C>T;NM_001198679:c.*1198C>T;NM_001198629:c.*1198C>T;NM_001198631:c.*1198C>T;NM_175635:c.*1198C>T;NM_175634:c.*1198C>T;NM_001198627:c.*1198C>T;NM_001198632:c.*1198C>T;NM_004349:c.*1198C>T;NM_001198630:c.*1198C>T;NM_001198634:c.*1198C>T;NM_175636:c.*1198C>T;NM_001198628:c.*1198C>T	.	.	0.999121688	0.000878304	7.71E-09	DISEASE: Note=A chromosomal aberration involving RUNX1T1 is a cause of acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1/AML1. {ECO:0000269|PubMed:1423235, ECO:0000269|PubMed:7541640, ECO:0000269|PubMed:8334990, ECO:0000269|PubMed:8353289}.; 	0.85092	0.58871	-1.001120478	8.321538099	35.00756	1.06236	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	23	chr8	92971272	chr8:92971272	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr8	97274483	97274483	G	A	intronic	PTDSS1	.	.	.	0.857749192	0.142246932	3.88E-06	DISEASE: Lenz-Majewski hyperostotic dwarfism (LMHD) [MIM:151050]: A syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. LMHD is characterized by the combination of sclerosing bone dysplasia, intellectual disability and distinct craniofacial, dental, cutaneous and distal limb anomalies. The progressive generalized hyperostosis associated with this syndrome affects the cranium, the vertebrae and the diaphyses of tubular bones, leading to severe growth restriction. {ECO:0000269|PubMed:24241535}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.26928	0.12774	-0.359940251	28.93371078	145.442	2.62713	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr8	97274483	chr8:97274483	G	A	.	PASS	AN=0;DP=39	GT	0/1
chr8	114389215	114389215	C	T	intronic	CSMD3	.	.	.	0.999999996	4.08E-09	1.04E-35	.	0.39932	0.10693	-3.486527925	0.347959424	4750.0149	13.94247	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	58	chr8	114389215	chr8:114389215	C	T	.	PASS	AN=0;DP=58	GT	0/1
chr8	143607953	143607953	C	A	exonic	ADGRB1	.	nonsynonymous SNV	ADGRB1:NM_001702:exon23:c.C3363A:p.D1121E	.	.	.	.	0.12027	0.1959	.	.	.	.	0.005	0.632	D	1.0	0.899	D	0.999	0.916	D	0.000	0.843	U	0.997	0.437	D	1.975	0.537	M	1.24	0.367	T	-3.2	0.647	D	0.124	0.140	-0.935	0.434	T	0.128	0.437	T	0.117	0.797	D	5.552	0.755	26.4	0.995	0.679	0.167	0.193	N	c	-0.483	-0.681	0.338	0.195	0.696	0.567	0	-5.02	0.027	-0.272	0.085	-1.079	0.019	0.493	0.267	0.985	0.512	11.631	0.502	GPCR, family 2-like	.	.	0.5	.	66	chr8	143607953	chr8:143607953	C	A	.	PASS	AN=0;DP=66	GT	0/1
chr8	144406691	144406691	G	C	exonic	TOP1MT	.	nonsynonymous SNV	TOP1MT:NM_001258447:exon6:c.C486G:p.I162M,TOP1MT:NM_052963:exon6:c.C780G:p.I260M,TOP1MT:NM_001258446:exon7:c.C486G:p.I162M	1.63E-19	0.001500191	0.998499809	.	0.18543	0.14812	-0.435396074	24.70511913	3501.83574	11.39955	0.052	0.395	T	0.95	0.519	P	0.864	0.597	P	0.125	0.189	U	0.739	0.338	D	2.215	0.627	M	0.91	0.449	T	-1.66	0.416	N	0.263	0.435	-0.797	0.553	T	0.150	0.478	T	0.005	0.141	T	2.172	0.322	17.33	0.991	0.510	0.737	0.358	D	c	-0.035	-0.191	0.993	0.331	0.707	0.730	0	1.66	0.230	0.250	0.179	0.797	0.323	0.998	0.411	0.184	0.214	0.936	0.012	DNA topoisomerase I, DNA binding, eukaryotic-type|DNA topoisomerase I, DNA binding, mixed alpha/beta motif, eukaryotic-type;DNA topoisomerase I, DNA binding, eukaryotic-type|DNA topoisomerase I, DNA binding, mixed alpha/beta motif, eukaryotic-type|DNA topoisomerase I, eukaryotic-type	.	.	0.5	90	74	chr8	144406691	chr8:144406691	G	C	90	PASS	AN=2;DP=74	GT	0/1
chr8	145537789	145537789	G	A	exonic	HSF1	.	synonymous SNV	HSF1:NM_005526:exon13:c.G1386A:p.G462G	0.586374295	0.413181557	0.000444148	.	0.11458	0.16496	-0.865195027	10.79853739	350.11867	3.96676	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr8	145537789	chr8:145537789	G	A	.	PASS	AN=0;DP=21	GT	0/1
chr9	8449660	8449660	T	C	intronic	PTPRD	.	.	.	0.999999982	1.80E-08	4.88E-23	.	0.89661	0.17382	-3.078871465	0.483604624	1565.5627	7.32256	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	25	chr9	8449660	chr9:8449660	T	C	63	PASS	AN=2;DP=25	GT	1/0
chr9	14086859	14086859	G	A	UTR3	NFIB	NM_001190737:c.*1449C>T;NM_005596:c.*1449C>T;NM_001282787:c.*1337C>T;NM_001190738:c.*1449C>T	.	.	0.990809167	0.009190352	4.81E-07	.	0.94482	0.41901	-0.449946534	24.00330267	16.65407	0.58684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr9	14086859	chr9:14086859	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr9	17332542	17332542	G	T	intronic	CNTLN	.	.	.	.	.	.	.	0.20604	0.17905	0.461041847	78.29087049	3754.49948	11.98604	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr9	17332542	chr9:17332542	G	T	.	PASS	AN=0;DP=27	GT	0/1
chr9	35792272	35792272	T	A	upstream	NPR2	dist=134	.	.	0.991660782	0.008339218	2.60E-11	DISEASE: Acromesomelic dysplasia, Maroteaux type (AMDM) [MIM:602875]: An autosomal recessive acromesomelic chondrodysplasia. Acromesomelic chondrodysplasias are rare hereditary skeletal disorders characterized by short stature, very short limbs and hand/foot malformations. The severity of limb abnormalities increases from proximal to distal with profoundly affected hands and feet showing brachydactyly and/or rudimentary fingers (knob-like fingers). AMDM is characterized by axial skeletal involvement with wedging of vertebral bodies. In AMDM all skeletal elements are present but show abnormal rates of linear growth. {ECO:0000269|PubMed:15146390}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epiphyseal chondrodysplasia, Miura type (ECDM) [MIM:615923]: An overgrowth syndrome characterized by tall stature, long hands and feet with arachnodactyly, macrodactyly of the great toes, scoliosis, coxa valga and slipped capital femoral epiphysis. {ECO:0000269|PubMed:22870295, ECO:0000269|PubMed:23827346, ECO:0000269|PubMed:24057292, ECO:0000269|PubMed:24259409}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Short stature with non-specific skeletal abnormalities (SNSK) [MIM:616255]: A condition characterized by short stature, defined as a height less than 2 SD below normal, and no endocrine abnormalities. {ECO:0000269|PubMed:24001744, ECO:0000269|PubMed:24471569}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.1999	0.26645	-1.043396569	7.71408351	52.97375	1.44484	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	173	chr9	35792272	chr9:35792272	T	A	.	PASS	AN=0;DP=173	GT	0/1
chr9	69082095	69082095	A	-	ncRNA_intronic	FRG1HP;PGM5P2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	15	chr9	69082094	chr9:69082094	CA	C	54	PASS	AN=2;DP=15	GT	0/1
chr9	86593171	86593171	C	T	UTR5	HNRNPK	NM_001318187:c.-4G>A;NM_002140:c.-4G>A;NM_031263:c.-4G>A;NM_001318186:c.-4G>A;NM_001318188:c.-4G>A;NM_031262:c.-4G>A	.	.	0.999782389	0.000217611	2.57E-10	.	0.8864	0.67288	-0.207437529	38.2814343	5.95251	0.22372	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	44	chr9	86593171	chr9:86593171	C	T	.	PASS	AN=0;DP=44	GT	0/1
chr9	117053128	117053128	C	A	exonic	COL27A1	.	synonymous SNV	COL27A1:NM_032888:exon48:c.C4407A:p.G1469G	0.999999361	6.39E-07	9.95E-23	DISEASE: Steel syndrome (STLS) [MIM:615155]: A syndrome characterized by dislocated hips and radial heads, fusion of carpal bones, short stature, scoliosis, and cervical spine anomalies. Facial features include prominent forehead, long oval- shaped face, hypertelorism and broad nasal bridge. {ECO:0000269|PubMed:24986830}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.70075	.	0.170613481	65.33970276	8956.48219	20.50775	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	20	chr9	117053128	chr9:117053128	C	A	.	PASS	AN=0;DP=20	GT	0/1
chr9	117143366	117143366	G	A	exonic	AKNA	.	nonsynonymous SNV	AKNA:NM_001317950:exon2:c.C248T:p.S83F,AKNA:NM_030767:exon2:c.C248T:p.S83F	0.02852574	0.971473491	7.69E-07	.	0.0634	0.0824	0.378330486	75.51899033	4847.69941	14.15107	0.255	0.168	T	0.001	0.067	B	0.003	0.080	B	0.850	0.090	N	1	0.090	N	1.525	0.387	L	2.65	0.332	T	-1.76	0.424	N	0.116	0.144	-1.009	0.273	T	0.047	0.200	T	0.004	0.086	T	0.779	0.168	9.333	0.770	0.113	0.041	0.094	N	c	-1.348	-1.382	1.000	0.411	0.672	0.522	0	1.13	0.197	0.793	0.264	-0.387	0.064	0.001	0.137	0.001	0.043	6.567	0.216	.	.	.	0.5	.	45	chr9	117143366	chr9:117143366	G	A	.	PASS	AN=0;DP=45	GT	0/1
chr9	130206266	130206266	C	T	intronic	ZNF79	.	.	.	0.017129421	0.960225592	0.022644988	.	0.34316	0.20051	0.134171522	63.57041755	46.29924	1.31066	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	98	chr9	130206266	chr9:130206266	C	T	64	PASS	AN=2;DP=98	GT	0/1
chr9	130571176	130571177	AG	-	intronic	FPGS	.	.	.	0.000112878	0.988716023	0.011171099	.	0.08683	0.26961	-0.534490515	20.70063694	105.84338	2.2299	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	11.73	68	chr9	130571175	chr9:130571175	TAG	T	11.73	PASS	AN=0;DP=68	GT	0/1
chr9	130905129	130905204	TGGCCCAGGACAAGAGGAATCTGGGGTGTGGGGAGAAGGGGTCTATGGGGTCAAGGAGACTATGCTGGCTGCAAAA	-	intergenic	PTGES2-AS1;LCN2	dist=12216;dist=6505	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	12.54	38	chr9	130905128	chr9:130905128	GTGGCCCAGGACAAGAGGAATCTGGGGTGTGGGGAGAAGGGGTCTATGGGGTCAAGGAGACTATGCTGGCTGCAAAA	G	12.54	PASS	AN=0;DP=38	GT	0/1
chr9	137600270	137600270	T	-	intronic	COL5A1	.	.	.	1	2.48E-13	8.59E-33	DISEASE: Ehlers-Danlos syndrome, classic type (EDS) [MIM:130000]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. {ECO:0000269|PubMed:10602121, ECO:0000269|PubMed:11992482, ECO:0000269|PubMed:15580559, ECO:0000269|PubMed:18972565, ECO:0000269|PubMed:9042913}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.69297	.	-3.009169053	0.524887945	863.84203	5.72906	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	20	chr9	137600269	chr9:137600269	GT	G	54	PASS	AN=2;DP=20	GT	0/1
chr9	139905432	139905432	G	A	exonic	ABCA2	.	nonsynonymous SNV	ABCA2:NM_001606:exon39:c.C6049T:p.R2017W,ABCA2:NM_212533:exon39:c.C6139T:p.R2047W	0.999999516	4.84E-07	6.11E-21	.	0.34587	0.29822	-4.237700156	0.123849965	470.40443	4.48778	0.002	0.721	D	0.476	0.418	P	0.014	0.188	B	0.367	0.136	U	0.998	0.222	N	0	0.065	N	-1.27	0.793	T	-0.43	0.144	N	0.197	0.495	-0.894	0.486	T	0.159	0.493	T	0.633	0.969	D	6.690	0.916	32	0.991	0.509	0.895	0.497	D	c	-0.164	-0.066	0.772	0.237	0.696	0.567	0	3.42	0.381	4.976	0.633	0.870	0.379	1.000	0.715	0.994	0.587	8.885	0.344	.	.	.	0.5	.	143	chr9	139905432	chr9:139905432	G	A	.	PASS	AN=0;DP=143	GT	0/1
chr9	140686493	140686493	T	-	intronic	EHMT1	.	.	.	0.999999904	9.60E-08	3.49E-19	DISEASE: Kleefstra syndrome (KLESTS) [MIM:610253]: A syndrome characterized by severe mental retardation, hypotonia, brachy(micro)cephaly, and facial dysmorphisms. Additionally, congenital heart defects, urogenital defects, epilepsy and behavioral problems are frequently observed. {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}. Note=The disease is caused by mutations affecting the gene represented in this entry (PubMed:16826528). The syndrome can be either caused by intragenic EHMT1 mutations leading to haploinsufficiency of the EHMT1 gene or by a submicroscopic 9q34.3 deletion. Although it is not known if and to what extent other genes in the 9q34.3 region contribute to the syndrome observed in deletion cases, EHMT1 seems to be the major determinant of the core disease phenotype (PubMed:19264732). {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}.; 	0.19698	0.1459	-1.582005788	3.13163482	397.32742	4.1876	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	14	chr9	140686492	chr9:140686492	CT	C	43	PASS	AN=2;DP=14	GT	0/1
chr10	11911550	11911550	C	-	exonic	PROSER2	.	frameshift deletion	PROSER2:NM_153256:exon4:c.453delC:p.P153Rfs*199	0.005463151	0.713979705	0.280557144	.	0.09537	.	.	.	802.73118	5.58207	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	44	chr10	11911549	chr10:11911549	AC	A	43	PASS	AN=2;DP=44	GT	0/1
chr10	16563920	16563920	C	T	UTR5	C1QL3	NM_001010908:c.-856G>A	.	.	0.718803252	0.267338417	0.013858331	.	0.58092	0.12378	.	.	0.76147	0.01334	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	22	chr10	16563920	chr10:16563920	C	T	.	PASS	AN=0;DP=22	GT	0/1
chr10	38404064	38404064	C	A	intronic	ZNF37A	.	.	.	0.001924415	0.906226625	0.09184896	.	0.12669	0.0957	0.088260113	60.56853031	287.83652	3.63338	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	101	chr10	38404064	chr10:38404064	C	A	.	PASS	AN=0;DP=101	GT	0/1
chr10	43318544	43318544	T	G	intronic	BMS1	.	.	.	0.995287036	0.004712964	6.45E-12	DISEASE: Aplasia cutis congenita, non-syndromic (ACC) [MIM:107600]: A disorder characterized by congenital absence of a portion of skin in a localized or widespread area of the body. The lesions are most commonly localized on the scalp, however aplasia cutis congenita can affect any part of the body. {ECO:0000269|PubMed:23785305}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	.	0.099178678	60.75725407	2238.17745	8.72857	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	87	57	chr10	43318544	chr10:43318544	T	G	87	PASS	AN=2;DP=57	GT	0/1
chr10	51093219	51093219	G	A	intronic	PARG	.	.	.	.	.	.	.	0.16017	0.13522	.	.	87.98386	2.00608	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	52	chr10	51093219	chr10:51093219	G	A	.	PASS	AN=0;DP=52	GT	0/1
chr10	71267365	71267366	GC	-	UTR3	TSPAN15	NM_001351263:c.*631_*632delGC;NM_012339:c.*631_*632delGC	.	.	0.001855808	0.902378587	0.095765605	.	0.29157	0.11343	0.350995466	74.37485256	209.06557	3.1214	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	32.61	22	chr10	71267364	chr10:71267364	TGC	T	32.61	PASS	AN=0;DP=22	GT	0/1
chr10	75835805	75835805	C	T	intronic	VCL	.	.	.	0.994870402	0.005129598	3.92E-11	DISEASE: Cardiomyopathy, dilated 1W (CMD1W) [MIM:611407]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11815424, ECO:0000269|PubMed:16236538}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 15 (CMH15) [MIM:613255]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:16712796}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.84455	.	-1.793112871	2.229299363	332.65362	3.87638	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr10	75835805	chr10:75835805	C	T	.	PASS	AN=0;DP=18	GT	0/1
chr10	77157785	77157785	T	-	UTR3	ZNF503	NM_032772:c.*722delA	.	.	0.887882313	0.110917243	0.001200444	.	0.92206	0.11115	.	.	889.95494	5.81207	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	13	chr10	77157784	chr10:77157784	CT	C	42	PASS	AN=2;DP=13	GT	0/1
chr10	87966306	87966306	G	A	exonic	GRID1	.	nonsynonymous SNV	GRID1:NM_017551:exon3:c.C335T:p.P112L	0.950796126	0.049203622	2.52E-07	.	0.40271	0.11711	-2.100076584	1.545175749	701.32829	5.26849	0.0	0.912	D	1.0	0.899	D	0.999	0.916	D	0.000	0.843	D	1	0.810	D	1.04	0.263	L	-2.92	0.918	D	-8.09	0.967	D	0.968	0.968	0.862	0.952	D	0.864	0.955	D	0.548	0.958	D	6.467	0.892	29.9	0.999	0.984	0.994	0.960	D	c	0.959	0.963	1.000	0.747	0.554	0.283	0	6.06	0.983	9.988	0.992	1.048	0.713	1.000	0.715	0.999	0.750	19.609	0.956	Periplasmic binding protein-like I|Receptor, ligand binding region	.	.	0.5	.	15	chr10	87966306	chr10:87966306	G	A	.	PASS	AN=0;DP=15	GT	0/1
chr11	372737	372737	C	T	exonic	B4GALNT4	.	nonsynonymous SNV	B4GALNT4:NM_178537:exon3:c.C331T:p.P111S	0.816930491	0.183069195	3.15E-07	.	0.13468	0.09235	.	.	1517.92316	7.2418	0.54	0.068	T	0.147	0.262	B	0.024	0.190	B	0.898	0.073	N	1	0.090	N	2.25	0.640	M	3.54	0.048	T	-2.63	0.564	D	0.412	0.470	-0.926	0.448	T	0.016	0.064	T	0.026	0.494	D	3.718	0.504	23.3	0.997	0.820	0.056	0.114	N	c	-0.661	-0.659	0.999	0.370	0.696	0.567	0	3.17	0.354	2.491	0.447	0.715	0.302	0.670	0.281	0.881	0.369	5.761	0.173	.	.	.	0.5	.	65	chr11	372737	chr11:372737	C	T	.	PASS	AN=0;DP=65	GT	0/1
chr11	792809	792809	T	-	intronic	SLC25A22	.	.	.	0.568405565	0.42907803	0.002516405	.	0.4027	0.12155	0.128714042	63.19886766	219.59154	3.20559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	99	chr11	792808	chr11:792808	CT	C	84	PASS	AN=2;DP=99	GT	0/1
chr11	792856	792856	C	-	intronic	SLC25A22	.	.	.	0.568405565	0.42907803	0.002516405	.	0.4027	0.12155	0.128714042	63.19886766	219.59154	3.20559	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	184	chr11	792855	chr11:792855	TC	T	84	PASS	AN=2;DP=184	GT	0/1
chr11	1264683	1264683	G	-	exonic	MUC5B	.	frameshift deletion	MUC5B:NM_002458:exon31:c.6573delG:p.N2192Tfs*41	0.999999706	2.94E-07	6.12E-25	DISEASE: Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. In some cases, the disorder can be rapidly progressive and characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. {ECO:0000269|PubMed:21506741, ECO:0000269|PubMed:21506748}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia and idiopathic pulmonary fibrosis, suggesting that dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis (PubMed:21506741). {ECO:0000269|PubMed:21506741}.; 	0.07831	.	16.52445195	99.97640953	6531.39188	16.99148	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	78	chr11	1264682	chr11:1264682	CG	C	64	PASS	AN=2;DP=78	GT	0/1
chr11	1478186	1478186	-	C	exonic	BRSK2	.	frameshift insertion	BRSK2:NM_001256629:exon19:c.1942dupC:p.P651Tfs*11,BRSK2:NM_001282218:exon19:c.1762dupC:p.P591Tfs*11	0.779570081	0.220416998	1.29E-05	.	0.16676	0.10676	-1.506435464	3.544468035	64.45039	1.64641	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	46	chr11	1478186	chr11:1478186	A	AC	44	PASS	AN=2;DP=46	GT	0/1
chr11	2329934	2329934	C	A	intronic	TSPAN32	.	.	.	0.000537261	0.88875402	0.110708719	.	0.07365	.	0.376678994	75.50719509	156.95947	2.73665	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	109	chr11	2329934	chr11:2329934	C	A	.	PASS	AN=0;DP=109	GT	0/1
chr11	2336474	2336474	A	G	intronic	TSPAN32	.	.	.	0.000537261	0.88875402	0.110708719	.	0.07365	.	0.376678994	75.50719509	156.95947	2.73665	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	234	chr11	2336474	chr11:2336474	A	G	73	PASS	AN=2;DP=234	GT	0/1
chr11	4827273	4827273	A	-	intergenic	OR52R1;OR51F2	dist=1663;dist=15343	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	17	chr11	4827272	chr11:4827272	GA	G	54	PASS	AN=2;DP=17	GT	0/1
chr11	18048061	18048061	G	A	exonic	TPH1	.	nonsynonymous SNV	TPH1:NM_004179:exon6:c.C779T:p.S260L	2.67E-05	0.924859058	0.075114211	.	0.42896	0.39606	-0.378346116	28.01368247	150.71244	2.68113	0.0	0.912	D	0.343	0.317	B	0.257	0.376	B	0.000	0.843	D	1	0.810	D	4.125	0.975	H	-6.22	0.996	D	-5.3	0.844	D	0.775	0.788	1.103	0.998	D	0.977	0.993	D	0.522	0.955	D	6.608	0.908	32	0.998	0.915	0.989	0.883	D	c	0.541	0.621	1.000	0.747	0.516	0.203	0	5.4	0.779	9.956	0.990	0.998	0.613	1.000	0.715	1.000	0.888	19.540	0.952	Aromatic amino acid hydroxylase, C-terminal	.	.	0.5	.	29	chr11	18048061	chr11:18048061	G	A	.	PASS	AN=0;DP=29	GT	0/1
chr11	62414680	62414680	G	A	exonic	INTS5	.	stopgain	INTS5:NM_030628:exon2:c.C2872T:p.Q958X	0.999284368	0.000715627	4.68E-09	.	0.31626	0.12936	-0.971800989	8.946685539	92.50703	2.06784	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.967	0.988	40	0.997	0.788	0.985	0.831	D	c	1.248	1.127	1.0	0.983	0.742	0.980	0	5.96	0.967	9.436	0.967	1.048	0.713	1.000	0.715	0.999	0.750	17.898	0.888	Integrator complex subunit 5, C-terminal	.	.	0.5	.	32	chr11	62414680	chr11:62414680	G	A	.	PASS	AN=0;DP=32	GT	0/1
chr11	65359372	65359372	G	A	intronic	EHBP1L1	.	.	.	8.08E-07	0.999807515	0.000191677	.	0.16998	0.08888	0.077132183	59.19438547	4618.64715	13.65497	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	28	chr11	65359372	chr11:65359372	G	A	.	PASS	AN=0;DP=28	GT	0/1
chr11	67763129	67763129	G	A	exonic	UNC93B1	.	unknown	UNKNOWN	0.513837376	0.482295391	0.003867233	DISEASE: Herpes simplex encephalitis 1 (HSE1) [MIM:610551]: A rare complication of human herpesvirus 1 (HHV-1) infection, occurring in only a small minority of HHV-1 infected individuals. HSE is characterized by hemorrhagic necrosis of parts of the temporal and frontal lobes. Onset is over several days and involves fever, headache, seizures, stupor, and often coma, frequently with a fatal outcome. {ECO:0000269|PubMed:16973841}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Mutations in UNC93B1 resulting in autosomal recessive UNC93B1 deficieny predispose otherwise healthy individuals to isolated herpes simplex encephalitis due to impaired IFNs production. UNC93B1 deficieny, however, does not compromise immunity to most pathogens, unlike most known primary immunodeficiencies.; 	.	0.17596	.	.	149.92935	2.66921	0.305	0.142	T	0.506	0.354	P	0.051	0.240	B	0.000	0.559	N	0.820	0.348	D	2.075	0.572	M	-1.37	0.802	T	-2.22	0.498	N	0.371	0.432	-1.009	0.273	T	0.022	0.091	T	0.031	0.532	D	1.957	0.296	15.94	0.990	0.496	0.962	0.676	D	c	-0.222	-0.153	1.000	0.747	0.713	0.817	0	3.56	0.397	5.222	0.649	1.038	0.658	1.000	0.715	0.011	0.114	10.105	0.415	.	.	.	0.5	.	113	chr11	67763129	chr11:67763129	G	A	.	PASS	AN=0;DP=113	GT	0/1
chr11	85346790	85346790	G	T	exonic	TMEM126B	.	nonsynonymous SNV	TMEM126B:NM_001256547:exon3:c.G339T:p.L113F,TMEM126B:NM_001350393:exon3:c.G252T:p.L84F,TMEM126B:NM_018480:exon4:c.G477T:p.L159F,TMEM126B:NM_001193537:exon5:c.G417T:p.L139F,TMEM126B:NM_001193538:exon5:c.G387T:p.L129F,TMEM126B:NM_001256546:exon5:c.G387T:p.L129F	0.000531076	0.456608892	0.542860032	.	0.06517	0.073	0.393270925	76.04977589	58.25686	1.54509	0.004	0.654	D	0.999	0.764	D	0.977	0.722	D	0.000	0.629	D	0.998	0.444	D	2.7	0.793	M	0.58	0.542	T	-3.76	0.712	D	0.8	0.789	-0.629	0.637	T	0.307	0.678	T	0.041	0.596	D	4.043	0.543	23.7	0.998	0.920	0.754	0.366	D	c	-0.103	-0.187	0.812	0.243	0.732	0.924	0	1.31	0.207	1.035	0.296	1.048	0.713	1.000	0.715	0.867	0.362	8.126	0.300	.	.	.	0.5	.	33	chr11	85346790	chr11:85346790	G	T	.	PASS	AN=0;DP=33	GT	0/1
chr11	96074739	96074739	C	G	exonic	MAML2	.	synonymous SNV	MAML2:NM_032427:exon1:c.G321C:p.P107P	0.998525114	0.001474885	1.12E-09	DISEASE: Note=A chromosomal aberration involving MAML2 is found in mucoepidermoid carcinomas, benign Warthin tumors and clear cell hidradenomas. Translocation t(11;19)(q21;p13) with CRTC1. The fusion protein consists of the N-terminus of CRTC1 joined to the C-terminus of MAML2. The reciprocal fusion protein consisting of the N-terminus of MAML2 joined to the C-terminus of CRTC1 has been detected in a small number of mucoepidermoid carcinomas. {ECO:0000269|PubMed:15729701}.; 	0.28735	0.13371	0.207589927	67.52182118	1240.98759	6.64881	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	15	chr11	96074739	chr11:96074739	C	G	62	PASS	AN=2;DP=15	GT	0/1
chr11	118914990	118914990	C	T	UTR3	HYOU1	NM_006389:c.*1315G>A;NM_001130991:c.*1315G>A	.	.	0.99977936	0.00022064	4.46E-13	.	0.5567	0.18042	-1.835411529	2.081858929	85.0696	1.96574	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	51	chr11	118914990	chr11:118914990	C	T	.	PASS	AN=0;DP=51	GT	0/1
chr11	120348214	120348214	G	A	exonic	ARHGEF12	.	nonsynonymous SNV	ARHGEF12:NM_001198665:exon35:c.G3454A:p.V1152I,ARHGEF12:NM_001301084:exon36:c.G3202A:p.V1068I,ARHGEF12:NM_015313:exon36:c.G3511A:p.V1171I	0.999998926	1.07E-06	8.61E-21	.	0.4712	.	-0.323344668	30.9447983	743.24174	5.41202	0.057	0.388	T	0.006	0.191	B	0.006	0.188	B	0.079	0.210	N	0.999	0.223	N	1.95	0.526	M	-0.19	0.659	T	-0.22	0.105	N	0.057	0.067	-0.979	0.352	T	0.118	0.415	T	0.012	0.295	T	2.294	0.337	18.13	0.992	0.557	0.827	0.416	D	c	-0.153	0.062	0.927	0.268	0.732	0.924	0	4.24	0.493	3.969	0.563	0.905	0.419	0.994	0.380	0.989	0.536	12.907	0.574	.	.	.	0.5	.	21	chr11	120348214	chr11:120348214	G	A	.	PASS	AN=0;DP=21	GT	0/1
chr11	128615242	128615284	CTCCCAGAAAATGGACCTCCCCAGGCCCCACCTCCCTCCATCA	-	intronic	FLI1	.	.	.	0.819814084	0.180006653	0.000179263	DISEASE: Ewing sarcoma (ES) [MIM:612219]: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors. {ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:1765382}. Note=The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving FLI1 is found in patients with Erwing sarcoma. Translocation t(11;22)(q24;q12) with EWSR1. {ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:1765382}.; 	0.6145	.	-0.890882376	10.30313753	37.50769	1.11686	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.87	22	chr11	128615241	chr11:128615241	TCTCCCAGAAAATGGACCTCCCCAGGCCCCACCTCCCTCCATCA	T	13.87	PASS	AN=0;DP=22	GT	0/1
chr12	4410611	4410611	C	T	UTR3	CCND2	NM_001759:c.*1436C>T	.	.	0.949000818	0.050836062	0.000163119	DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (MPPH3) [MIM:615938]: A syndrome characterized by megalencephaly, ventriculomegaly that may lead to hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome. {ECO:0000269|PubMed:24705253}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.93215	0.74954	-0.185391282	39.67916962	14.77663	0.53228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	29	chr12	4410611	chr12:4410611	C	T	.	PASS	AN=0;DP=29	GT	0/1
chr12	14941935	14941935	C	-	exonic	WBP11	.	frameshift deletion	WBP11:NM_016312:exon11:c.1442delG:p.G481Vfs*25	0.999928146	7.19E-05	1.73E-11	.	0.58677	0.11579	-0.137658575	43.57159707	100.52915	2.1724	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	28	chr12	14941934	chr12:14941934	AC	A	60	PASS	AN=2;DP=28	GT	0/1
chr12	25361202	25361202	G	A	UTR3	KRAS	NM_033360:c.*1648C>T;NM_004985:c.*1527C>T	.	.	0.001061193	0.603148256	0.395790551	DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:8955068}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. {ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}.; DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. CFC2 patients often do not have the skin abnormalities, such as ichthyosis, hyperkeratosis, and hemangioma observed in CFC1. {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:21797849}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=KRAS mutations are involved in cancer development. {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, ECO:0000269|PubMed:7773929}.; 	0.99997	0.53296	-0.141298762	42.87567823	3.46519	0.12617	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr12	25361202	chr12:25361202	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr12	40928541	40928541	G	A	exonic	MUC19	.	unknown	UNKNOWN	.	.	.	.	0.11557	.	.	.	41933.48624	39.90294	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr12	40928541	chr12:40928541	G	A	.	PASS	AN=0;DP=45	GT	0/1
chr12	49691392	49691392	C	G	ncRNA_exonic	LOC101927267	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	44	chr12	49691392	chr12:49691392	C	G	73	PASS	AN=2;DP=44	GT	0/1
chr12	50149603	50149603	C	G	intronic	TMBIM6	.	.	.	0.016169744	0.959289242	0.024541014	.	0.09972	0.13992	-0.251530012	35.42108988	61.1273	1.59193	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	57	chr12	50149603	chr12:50149603	C	G	53	PASS	AN=2;DP=57	GT	0/1
chr12	52389579	52389579	C	G	UTR3	ACVR1B	NM_020328:c.*1685C>G;NM_004302:c.*1685C>G;NM_020327:c.*1685C>G	.	.	0.998904331	0.001095656	1.32E-08	DISEASE: Note=ACVRIB is abundantly expressed in systemic sclerosis patient fibroblasts and production of collagen is also induced by activin-A/INHBA. This suggests that the activin/ACRV1B signaling mechanism is involved in systemic sclerosis. {ECO:0000269|PubMed:21377836}.; 	0.88541	0.29686	-0.405853867	26.23260203	17.03945	0.59931	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr12	52389579	chr12:52389579	C	G	.	PASS	AN=0;DP=26	GT	0/1
chr12	93873164	93873164	C	T	exonic	MRPL42	.	synonymous SNV	MRPL42:NM_014050:exon4:c.C135T:p.C45C,MRPL42:NM_172177:exon4:c.C135T:p.C45C	0.027881567	0.797373303	0.17474513	.	0.03676	0.06595	-0.251530012	35.42108988	54.00078	1.46532	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr12	93873164	chr12:93873164	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr12	110895322	110895322	G	A	exonic	GPN3	.	nonsynonymous SNV	GPN3:NM_001164372:exon4:c.C560T:p.S187L,GPN3:NM_001164373:exon4:c.C473T:p.S158L,GPN3:NM_016301:exon4:c.C443T:p.S148L	0.000100472	0.804648765	0.195250764	.	0.5105	0.10747	-0.381986487	27.68931352	60.55868	1.58137	0.349	0.185	T	0.074	0.226	B	0.098	0.289	B	0.000	0.843	D	1	0.810	D	2.465	0.718	M	1.94	0.227	T	-2.47	0.540	N	0.338	0.816	-1.073	0.088	T	0.062	0.260	T	0.019	0.413	T	5.074	0.684	25.3	0.956	0.267	0.992	0.920	D	c	0.085	0.264	1.0	0.983	0.745	0.986	0	5.68	0.880	7.267	0.777	0.994	0.605	1.000	0.715	0.999	0.750	19.778	0.964	P-loop containing nucleoside triphosphate hydrolase	.	.	0.5	.	70	chr12	110895322	chr12:110895322	G	A	.	PASS	AN=0;DP=70	GT	0/1
chr12	118405932	118405932	G	A	exonic	KSR2	.	synonymous SNV	KSR2:NM_173598:exon1:c.C42T:p.T14T	0.999946625	5.34E-05	1.70E-12	.	0.40754	0.12029	.	.	183.49029	2.93982	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	24	chr12	118405932	chr12:118405932	G	A	.	PASS	AN=0;DP=24	GT	0/1
chr12	122017564	122017564	T	C	intronic	KDM2B	.	.	.	0.999785914	0.000214086	8.39E-14	.	0.3817	0.10945	-2.166248113	1.421325784	100.32428	2.17057	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	222	chr12	122017564	chr12:122017564	T	C	65	PASS	AN=2;DP=222	GT	0/1
chr13	24853006	24853006	T	C	intronic	SPATA13	.	.	.	0.528844213	0.471126751	2.90E-05	.	0.28685	0.1118	2.008142452	97.67044114	1024.01032	6.15271	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	61	chr13	24853006	chr13:24853006	T	C	42	PASS	AN=2;DP=61	GT	0/1
chr13	76140768	76140768	C	T	intronic	UCHL3	.	.	.	1.95E-05	0.702089901	0.297890577	.	0.61491	0.11954	-0.163345027	41.24793583	18.24807	0.63412	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr13	76140768	chr13:76140768	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr13	98119932	98119932	T	-	UTR3	RAP2A	NM_021033:c.*3236delT	.	.	0.717339657	0.268600965	0.014059378	.	0.15	0.18963	0.013025609	54.62962963	2.30275	0.0782	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	14	chr13	98119931	chr13:98119931	CT	C	53	PASS	AN=2;DP=14	GT	0/1
chr13	107822287	107822287	A	T	UTR3	FAM155A	NM_001080396:c.*558T>A	.	.	0.800415326	0.199346781	0.000237893	.	0.22573	.	-0.005381972	53.50908233	761.08845	5.47031	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	99	chr13	107822287	chr13:107822287	A	T	.	PASS	AN=0;DP=99	GT	0/1
chr13	113882334	113882334	G	A	exonic	CUL4A	.	nonsynonymous SNV	CUL4A:NM_001008895:exon4:c.G413A:p.C138Y,CUL4A:NM_001278513:exon4:c.G113A:p.C38Y,CUL4A:NM_001278514:exon4:c.G113A:p.C38Y,CUL4A:NM_003589:exon4:c.G113A:p.C38Y	0.999412877	0.000587123	5.85E-10	.	0.61067	0.26405	-0.422438699	25.64284029	1807.63636	7.84549	0.049	0.398	D	0.052	0.210	B	0.067	0.261	B	0.000	0.843	D	1	0.810	D	2.08	0.576	M	-0.75	0.733	T	-5.39	0.850	D	0.956	0.956	-0.545	0.670	T	0.342	0.708	T	0.036	0.568	D	2.221	0.328	17.64	0.815	0.133	0.995	0.968	D	c	0.027	0.179	1.0	0.983	0.707	0.730	0	5.51	0.817	9.684	0.979	1.045	0.669	1.000	0.715	0.960	0.441	19.454	0.949	Cullin repeat-like-containing domain|Cullin, N-terminal	.	.	0.5	.	21	chr13	113882334	chr13:113882334	G	A	.	PASS	AN=0;DP=21	GT	0/1
chr14	33836421	33836421	A	T	exonic	NPAS3	.	nonsynonymous SNV	NPAS3:NM_001165893:exon3:c.A325T:p.S109C,NPAS3:NM_022123:exon3:c.A319T:p.S107C,NPAS3:NM_001164749:exon4:c.A415T:p.S139C,NPAS3:NM_173159:exon4:c.A376T:p.S126C	0.98054867	0.019451206	1.24E-07	.	0.30103	0.1462	-1.350267166	4.600141543	902.6267	5.84777	0.005	0.784	D	0.982	0.647	D	0.789	0.654	P	0.000	0.843	D	0.999	0.504	D	1.15	0.294	L	3.35	0.080	T	-2.44	0.548	N	0.703	0.771	-0.755	0.577	T	0.179	0.526	T	0.021	0.442	T	5.178	0.699	25.5	0.993	0.574	0.975	0.748	D	c	0.571	0.625	0.998	0.359	0.487	0.133	0	5.53	0.825	6.911	0.754	1.088	0.866	1.000	0.715	0.999	0.750	15.662	0.769	Myc-type, basic helix-loop-helix (bHLH) domain	.	.	0.5	.	31	chr14	33836421	chr14:33836421	A	T	.	PASS	AN=0;DP=31	GT	0/1
chr14	39591562	39591562	-	T	intronic	GEMIN2	.	.	.	0.006609197	0.97473644	0.018654363	.	0.1302	0.1438	0.016664174	55.21939137	6043.31497	16.22939	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	25.34	29	chr14	39591562	chr14:39591562	C	CT	25.34	PASS	AN=0;DP=29	GT	0/1
chr14	71500710	71500710	C	T	exonic	PCNX1	.	nonsynonymous SNV	PCNX1:NM_001308160:exon16:c.C3398T:p.S1133F,PCNX1:NM_014982:exon18:c.C3731T:p.S1244F	.	.	.	.	0.12609	0.10474	-1.951619288	1.869544704	.	.	0.006	0.614	D	0.997	0.715	D	0.994	0.807	D	0.000	0.629	D	1	0.810	D	1.905	0.510	L	3.26	0.108	T	-2.64	0.566	D	0.23	0.723	-1.128	0.019	T	0.080	0.318	T	0.046	0.625	D	6.610	0.908	32	0.999	0.935	0.992	0.932	D	c	0.701	0.704	1.000	0.747	0.732	0.924	0	5.2	0.716	5.472	0.663	0.935	0.490	1.000	0.715	0.998	0.697	18.749	0.917	.	.	.	0.5	.	46	chr14	71500710	chr14:71500710	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr14	88945982	88945982	C	T	exonic	PTPN21	.	nonsynonymous SNV	PTPN21:NM_007039:exon13:c.G1793A:p.R598H	2.36E-07	0.999953846	4.59E-05	.	0.15764	0.14576	0.435344483	77.36494456	3246.49545	10.85309	0.003	0.682	D	1.0	0.899	D	0.996	0.832	D	0.000	0.843	D	1.000	0.513	D	2.74	0.803	M	-1.18	0.783	T	-2.89	0.606	D	0.626	0.646	0.357	0.884	D	0.639	0.874	D	0.402	0.934	D	7.427	0.951	34	1.000	1.000	0.991	0.913	D	c	0.772	0.719	1.000	0.747	0.718	0.821	0	5.26	0.734	6.106	0.710	0.852	0.362	1.000	0.715	0.921	0.396	18.871	0.922	.	.	.	0.5	.	67	chr14	88945982	chr14:88945982	C	T	.	PASS	AN=0;DP=67	GT	0/1
chr14	88945998	88945998	C	T	exonic	PTPN21	.	nonsynonymous SNV	PTPN21:NM_007039:exon13:c.G1777A:p.D593N	2.36E-07	0.999953846	4.59E-05	.	0.15764	0.14576	0.435344483	77.36494456	3246.49545	10.85309	0.002	0.721	D	1.0	0.899	D	0.995	0.818	D	0.000	0.843	D	1.000	0.537	D	2.865	0.834	M	-1.6	0.822	D	-3.51	0.683	D	0.094	0.130	0.603	0.919	D	0.736	0.910	D	0.501	0.952	D	6.622	0.909	32	0.999	0.975	0.991	0.913	D	c	0.722	0.635	1.000	0.747	0.718	0.821	0	5.26	0.734	7.837	0.849	0.852	0.362	1.000	0.715	0.976	0.476	18.871	0.922	.	.	.	0.5	.	68	chr14	88945998	chr14:88945998	C	T	.	PASS	AN=0;DP=68	GT	0/1
chr14	94245463	94245463	C	T	intronic	PRIMA1	.	.	.	0.367086766	0.583623514	0.049289721	.	0.17164	0.15948	-0.163345027	41.24793583	5.69887	0.21345	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr14	94245463	chr14:94245463	C	T	.	PASS	AN=0;DP=64	GT	0/1
chr15	42037557	42037557	C	A	intronic	MGA	.	.	.	1	3.53E-10	3.41E-27	.	0.96192	.	-0.613924518	17.48053786	3694.31204	11.84454	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	115	chr15	42037557	chr15:42037557	C	A	.	PASS	AN=0;DP=115	GT	0/1
chr15	43021459	43021459	C	T	exonic	CDAN1	.	nonsynonymous SNV	CDAN1:NM_138477:exon18:c.G2509A:p.A837T	0.928144193	0.071855806	1.10E-09	.	0.11601	0.18383	-0.828637633	11.54163718	8611.31398	20.08023	0.519	0.073	T	0.001	0.067	B	0.004	0.093	B	0.000	0.449	N	0.971	0.388	D	0	0.065	N	-1.05	0.767	T	-0.18	0.098	N	0.051	0.126	-0.927	0.446	T	0.210	0.570	T	0.041	0.597	D	2.696	0.385	20.8	0.829	0.139	0.714	0.347	D	c	-0.437	-0.302	0.999	0.398	0.646	0.442	0	0.808	0.178	0.466	0.216	0.921	0.432	0.993	0.376	0.987	0.523	2.458	0.042	Codanin-1, C-terminal domain	.	.	0.5	.	59	chr15	43021459	chr15:43021459	C	T	.	PASS	AN=0;DP=59	GT	0/1
chr15	45400207	45400207	G	A	intronic	DUOX2	.	.	.	1.90E-37	3.81E-06	0.999996187	DISEASE: Thyroid dyshormonogenesis 6 (TDH6) [MIM:607200]: A disorder due to a defective conversion of accumulated iodide to organically bound iodine. The iodide organification defect can be partial or complete. {ECO:0000269|PubMed:12110737, ECO:0000269|PubMed:16134168, ECO:0000269|PubMed:16322276, ECO:0000269|PubMed:20187165}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.15059	0.21524	0.227640447	68.52441614	1216.76018	6.60084	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr15	45400207	chr15:45400207	G	A	.	PASS	AN=0;DP=26	GT	0/1
chr15	66207746	66207746	C	T	intronic	MEGF11	.	.	.	2.52E-24	0.000112093	0.999887907	.	0.35561	0.08845	-0.635637306	16.76102854	4063.5662	12.63975	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chr15	66207746	chr15:66207746	C	T	.	PASS	AN=0;DP=18	GT	0/1
chr15	75981256	75981256	G	T	exonic	CSPG4	.	nonsynonymous SNV	CSPG4:NM_001897:exon3:c.C2150A:p.A717E	8.90E-05	0.999905547	5.48E-06	.	0.14288	0.14191	0.347031518	73.79098844	3644.03559	11.72399	0.417	0.099	T	0.808	0.433	P	0.274	0.383	B	0.433	0.127	N	1	0.090	N	2.6	0.763	M	1.79	0.255	T	-0.4	0.138	N	0.377	0.437	-1.081	0.072	T	0.051	0.217	T	0.010	0.255	T	-0.941	0.034	0.021	0.756	0.108	0.778	0.380	D	c	-0.083	-0.098	0.992	0.328	0.598	0.340	0	4.56	0.555	4.615	0.607	0.970	0.593	0.998	0.411	0.049	0.163	10.038	0.411	.	.	.	0.5	.	46	chr15	75981256	chr15:75981256	G	T	.	PASS	AN=0;DP=46	GT	0/1
chr15	91575679	91575681	CCT	-	intergenic	LOC101926911;SV2B	dist=1310;dist=67137	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	38	chr15	91575678	chr15:91575678	GCCT	G	44	PASS	AN=2;DP=38	GT	0/1
chr16	336252	336252	G	C	intronic	PDIA2	.	.	.	2.53E-21	1.80E-05	0.999982002	.	0.14665	0.10678	2.702925512	98.90304317	3052.49003	10.50276	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	95	97	chr16	336252	chr16:336252	G	C	95	PASS	AN=2;DP=97	GT	0/1
chr16	15474958	15474960	AAA	-	intergenic	NPIPA5;MPV17L	dist=2807;dist=14651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	14.21	40	chr16	15474957	chr16:15474957	TAAA	T,TAAAA	14.21	PASS	AN=0;DP=40	GT	0/1/.
chr16	15474960	15474960	-	A	intergenic	NPIPA5;MPV17L	dist=2809;dist=14651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	14.21	40	chr16	15474957	chr16:15474957	TAAA	T,TAAAA	14.21	PASS	AN=0;DP=40	GT	0/1/.
chr16	18882785	18882785	C	A	exonic	SMG1	.	nonsynonymous SNV	SMG1:NM_015092:exon16:c.G2203T:p.A735S	1	4.40E-14	1.05E-36	.	.	.	-2.975494782	0.542580797	910.18577	5.86659	0.044	0.410	D	0.093	0.238	B	0.013	0.154	B	0.000	0.629	U	0.994	0.420	D	1.32	0.331	L	-0.22	0.665	T	-0.99	0.262	N	0.296	0.560	-0.924	0.450	T	0.164	0.502	T	0.015	0.361	T	3.760	0.509	23.3	0.991	0.533	0.987	0.862	D	c	-0.054	0.166	0.976	0.296	0.707	0.730	0	5.21	0.719	5.719	0.679	0.927	0.437	1.000	0.715	1.000	0.888	19.116	0.933	.	.	.	0.5	.	71	chr16	18882785	chr16:18882785	C	A	.	PASS	AN=0;DP=71	GT	0/1
chr16	20911490	20911490	G	C	intronic	DCUN1D3;LYRM1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	113	chr16	20911490	chr16:20911490	G	C	65	PASS	AN=2;DP=113	GT	0/1
chr16	21624014	21624014	T	A	exonic	METTL9	.	nonsynonymous SNV	METTL9:NM_001077180:exon2:c.T214A:p.F72I,METTL9:NM_001288659:exon2:c.T94A:p.F32I,METTL9:NM_001288660:exon2:c.T94A:p.F32I,METTL9:NM_016025:exon2:c.T214A:p.F72I	0.377292455	0.611945921	0.010761624	.	0.26755	0.1138	-0.141298762	42.87567823	2.36913	0.08046	0.006	0.632	D	0.989	0.764	D	0.985	0.749	D	0.000	0.843	D	1	0.810	D	2.79	0.817	M	.	.	.	-4.65	0.794	D	0.757	0.801	-0.007	0.821	T	0.460	0.790	T	0.059	0.675	D	6.339	0.875	29.3	0.992	0.544	0.965	0.693	D	c	0.877	0.857	1.000	0.747	0.737	0.974	0	6.02	0.975	7.674	0.830	1.061	0.807	1.000	0.715	1.000	0.888	14.497	0.671	.	.	.	0.5	.	73	chr16	21624014	chr16:21624014	T	A	.	PASS	AN=0;DP=73	GT	0/1
chr16	30990543	30990543	C	T	exonic	SETD1A	.	nonsynonymous SNV	SETD1A:NM_014712:exon14:c.C3436T:p.R1146C	0.999996231	3.77E-06	5.40E-16	.	0.31946	.	-2.934884757	0.560273649	360.97151	4.02191	0.129	0.268	T	0.002	0.090	B	0.001	0.040	B	0.008	0.313	N	1	0.090	N	0.895	0.225	L	-3.42	0.944	D	-1.28	0.322	N	0.246	0.301	-0.071	0.808	T	0.721	0.904	D	0.722	0.978	D	0.938	0.184	10.30	0.618	0.066	0.083	0.140	N	c	-1.359	-1.356	0.843	0.249	0.696	0.567	0	3.05	0.341	0.045	0.138	-1.104	0.018	0.000	0.063	0.001	0.043	10.509	0.438	.	.	.	0.5	75	83	chr16	30990543	chr16:30990543	C	T	75	PASS	AN=2;DP=83	GT	0/1
chr16	33497515	33497515	C	A	intergenic	LOC390705;ENPP7P13	dist=198813;dist=74329	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr16	33497515	chr16:33497515	C	A	.	PASS	AN=0;DP=39	GT	0/1
chr16	57054565	57054565	C	T	intronic	NLRC5	.	.	.	6.72E-05	0.999932818	2.78E-09	.	0.07927	0.08967	0.514279338	80.30195801	898.09245	5.83754	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	63	chr16	57054565	chr16:57054565	C	T	.	PASS	AN=0;DP=63	GT	0/1
chr16	66801325	66801325	C	G	exonic	TERB1	.	nonsynonymous SNV	TERB1:NM_001136505:exon16:c.G1773C:p.R591S	.	.	.	.	.	.	.	.	.	.	.	.	.	0.131	0.256	B	0.039	0.223	B	.	.	.	1	0.810	D	2.19	0.618	M	.	.	.	.	.	.	0.631	0.649	-1.052	0.140	T	0.127	0.433	T	0.013	0.319	T	2.334	0.342	18.39	0.802	0.126	0.134	0.176	N	c	-0.803	-0.834	0.005	0.109	0.487	0.133	0	-4.68	0.031	-1.002	0.038	-0.379	0.065	0.223	0.243	0.976	0.476	11.526	0.496	.	.	.	0.5	.	34	chr16	66801325	chr16:66801325	C	G	.	PASS	AN=0;DP=34	GT	0/1
chr16	67212597	67212597	C	-	intronic	KIAA0895L	.	.	.	0.018433058	0.961138313	0.02042863	.	.	.	0.150760231	64.51403633	718.9968	5.32337	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	44	chr16	67212596	chr16:67212596	TC	T	42	PASS	AN=2;DP=44	GT	0/1
chr16	67670535	67670536	CA	-	intronic	CTCF	.	.	.	0.997924958	0.002075029	1.27E-08	DISEASE: Mental retardation, autosomal dominant 21 (MRD21) [MIM:615502]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Additional MRD21 features include short stature, microcephaly, and developmental delay. {ECO:0000269|PubMed:23746550}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.78428	0.25142	-0.293801652	32.93819297	9.66001	0.35497	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.55	32	chr16	67670534	chr16:67670534	TCA	T	13.55	PASS	AN=0;DP=32	GT	0/1
chr16	74943751	74943751	C	T	exonic	WDR59	.	nonsynonymous SNV	WDR59:NM_001324171:exon15:c.G1454A:p.R485H,WDR59:NM_030581:exon15:c.G1454A:p.R485H	3.44E-11	0.995036935	0.004963065	.	0.21989	0.10981	-1.256630467	5.343241331	409.53463	4.24211	0.003	0.682	D	0.979	0.571	D	0.451	0.443	P	0.000	0.843	D	1	0.810	D	2.475	0.721	M	0.98	0.421	T	-3.82	0.720	D	0.276	0.699	-0.738	0.586	T	0.170	0.511	T	0.029	0.515	D	7.682	0.954	35	0.999	0.999	0.994	0.956	D	c	0.720	0.753	1.000	0.747	0.732	0.924	0	5.66	0.872	7.749	0.839	0.935	0.490	1.000	0.715	1.000	0.888	20.115	0.979	RWD domain|Ubiquitin-conjugating enzyme/RWD-like	.	.	0.5	.	55	chr16	74943751	chr16:74943751	C	T	.	PASS	AN=0;DP=55	GT	0/1
chr17	4646580	4646580	C	-	intronic	ZMYND15	.	.	.	1.44E-05	0.998157386	0.001828251	DISEASE: Spermatogenic failure 14 (SPGF14) [MIM:615842]: A disorder resulting in the absence (azoospermia) or reduction (oligozoospermia) of sperm in the semen, leading to male infertility. {ECO:0000269|PubMed:24431330}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.18983	.	-0.951568548	9.271054494	291.84505	3.65548	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	31	chr17	4646579	chr17:4646579	TC	T	44	PASS	AN=2;DP=31	GT	0/1
chr17	10204985	10204985	C	T	exonic	MYH13	.	synonymous SNV	MYH13:NM_003802:exon40:c.G5703A:p.R1901R	1.89E-29	0.014239931	0.985760069	.	0.48597	0.1881	-0.635977455	16.74333569	5547.032	15.40045	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr17	10204985	chr17:10204985	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr17	19091405	19091405	C	G	intergenic	LOC79999;LOC79999	dist=25468;dist=27538	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	310	chr17	19091405	chr17:19091405	C	G	.	PASS	AN=0;DP=310	GT	0/1
chr17	21205359	21205364	GGGGCT	-	intronic	MAP2K3	.	.	.	0.000496053	0.968531857	0.03097209	DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.; 	0.23537	0.33997	0.108486928	61.90728946	81.19169	1.90782	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	8	chr17	21205358	chr17:21205358	GGGGGCT	G	42	PASS	AN=2;DP=8	GT	0/1
chr17	39216243	39216284	GCAGCAGCCTCCCCCGTAGCTCAGGGAGGACAAGGTGGAGCC	-	exonic	KRTAP2-3	.	nonframeshift deletion	KRTAP2-3:NM_001165252:exon1:c.19_60del:p.G7_C20del	0.0777172	0.541195919	0.381086882	.	0.24626	.	.	.	4812.04517	14.06529	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	55	chr17	39216242	chr17:39216242	GGCAGCAGCCTCCCCCGTAGCTCAGGGAGGACAAGGTGGAGCC	G	59	PASS	AN=2;DP=55	GT	0/1
chr17	42267817	42267817	C	T	intronic	TMUB2	.	.	.	0.001301139	0.647548425	0.351150436	.	0.39207	.	-0.337894035	30.37272942	380.91104	4.11369	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	33	chr17	42267817	chr17:42267817	C	T	.	PASS	AN=0;DP=33	GT	0/1
chr17	45727515	45727515	C	G	UTR5	KPNB1	NM_002265:c.-96C>G	.	.	0.999994328	5.67E-06	7.22E-15	.	0.99948	0.5595	-0.624497208	17.16206653	28.74247	0.91953	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	144	chr17	45727515	chr17:45727515	C	G	74	PASS	AN=2;DP=144	GT	0/1
chr17	47755280	47755280	C	T	intronic	SPOP	.	.	.	0.992531223	0.007467347	1.43E-06	.	0.21933	0.18619	-0.185391282	39.67916962	25.23464	0.82534	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	75	chr17	47755280	chr17:47755280	C	T	.	PASS	AN=0;DP=75	GT	0/1
chr17	56083848	56083848	A	-	exonic	SRSF1	.	frameshift deletion	SRSF1:NM_001078166:exon2:c.235delT:p.Y79Tfs*58,SRSF1:NM_006924:exon2:c.235delT:p.Y79Tfs*58	0.991994023	0.008004282	1.70E-06	.	0.85062	0.04472	-0.009020804	52.8544468	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	114.1	80	chr17	56083847	chr17:56083847	TA	T	114.1	PASS	AN=0;DP=80	GT	0/1
chr17	61772392	61772392	C	T	UTR3	MAP3K3	NM_001330431:c.*1255C>T;NM_203351:c.*1255C>T;NM_002401:c.*1255C>T	.	.	0.999526987	0.000473013	6.99E-11	.	0.79837	0.23984	-1.06726444	7.372021703	91.94105	2.06355	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr17	61772392	chr17:61772392	C	T	.	PASS	AN=0;DP=46	GT	0/1
chr17	65073947	65073947	C	T	UTR3	HELZ	NM_014877:c.*421G>A;NM_001330447:c.*421G>A	.	.	1	3.48E-11	7.19E-27	.	0.33626	0.09834	-1.210720546	5.708893607	2913.40807	10.24388	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	75	chr17	65073947	chr17:65073947	C	T	.	PASS	AN=0;DP=75	GT	0/1
chr17	75494803	75494803	C	T	UTR3	SEPT9	NM_001293695:c.*63C>T;NM_001113491:c.*63C>T;NM_001113492:c.*63C>T;NM_006640:c.*63C>T;NM_001113493:c.*63C>T;NM_001113494:c.*63C>T;NM_001293696:c.*63C>T;NM_001113496:c.*63C>T;NM_001293697:c.*63C>T;NM_001293698:c.*63C>T;NM_001113495:c.*63C>T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	70	91	chr17	75494803	chr17:75494803	C	T	70	PASS	AN=2;DP=91	GT	0/1
chr17	76446798	76446798	G	T	exonic	DNAH17	.	nonsynonymous SNV	DNAH17:NM_173628:exon67:c.C10865A:p.T3622N	.	.	.	.	0.10041	.	.	.	8793.71322	20.21811	.	.	.	0.009	0.139	B	0.02	0.179	B	0.002	0.385	N	0.895	0.360	D	1.065	0.271	L	-0.24	0.668	T	.	.	.	0.152	0.181	-0.930	0.441	T	0.155	0.486	T	0.006	0.164	T	1.568	0.250	13.68	0.934	0.225	0.921	0.546	D	c	-0.349	-0.193	0.171	0.177	0.615	0.372	0	2.33	0.279	1.201	0.317	0.953	0.551	0.877	0.307	1.000	0.888	9.725	0.393	.	.	.	0.5	.	30	chr17	76446798	chr17:76446798	G	T	.	PASS	AN=0;DP=30	GT	0/1
chr17	78440791	78440791	T	A	UTR3	NPTX1	NM_002522:c.*3822A>T	.	.	0.426444497	0.566089052	0.007466451	.	0.3732	0.18467	-0.291981272	33.20358575	668.26251	5.17027	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	37	chr17	78440791	chr17:78440791	T	A	.	PASS	AN=0;DP=37	GT	0/1
chr17	80887089	80887089	G	A	exonic	TBCD	.	nonsynonymous SNV	TBCD:NM_005993:exon31:c.G2794A:p.D932N	6.98E-05	0.999929838	3.18E-07	.	0.12203	0.11011	-1.453286053	3.892427459	630.24341	5.05995	0.095	0.312	T	0.007	0.158	B	0.037	0.218	B	0.030	0.254	N	1	0.090	N	2.395	0.694	M	-0.26	0.672	T	-1.57	0.379	N	0.071	0.077	-0.822	0.538	T	0.219	0.583	T	0.034	0.553	D	1.823	0.280	15.12	0.991	0.533	0.166	0.193	N	c	-0.469	-0.459	0.405	0.202	0.707	0.730	0	5.13	0.696	2.663	0.462	1.048	0.713	0.513	0.268	0.016	0.126	9.679	0.390	Armadillo-type fold|Tubulin-specific chaperone D, C-terminal;Tubulin-specific chaperone D, C-terminal	.	.	0.5	.	40	chr17	80887089	chr17:80887089	G	A	.	PASS	AN=0;DP=40	GT	0/1
chr18	14808654	14808654	T	C	intronic	ANKRD30B	.	.	.	1.49E-09	0.94288369	0.057116308	.	.	.	1.06196211	91.507431	2417.32649	9.13836	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	50	chr18	14808654	chr18:14808654	T	C	51	PASS	AN=2;DP=50	GT	0/1
chr18	43577691	43577691	T	A	intronic	PSTPIP2	.	.	.	0.107611557	0.892114743	0.0002737	.	0.08446	0.08464	0.060756528	58.52795471	1683.83562	7.56284	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	67	chr18	43577691	chr18:43577691	T	A	.	PASS	AN=0;DP=67	GT	0/1
chr18	43577726	43577726	T	A	exonic	PSTPIP2	.	stopgain	PSTPIP2:NM_024430:exon9:c.A631T:p.K211X	0.107611557	0.892114743	0.0002737	.	0.08446	0.08464	0.060756528	58.52795471	1683.83562	7.56284	.	.	.	.	.	.	.	.	.	0.028	0.257	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13.132	0.989	41	0.996	0.766	0.950	0.627	D	c	0.800	0.676	1.000	0.747	0.706	0.609	0	5.5	0.813	5.053	0.639	1.061	0.807	1.000	0.715	1.000	0.888	14.880	0.700	F-BAR domain	.	.	0.5	.	69	chr18	43577726	chr18:43577726	T	A	.	PASS	AN=0;DP=69	GT	0/1
chr19	1008218	1008218	C	T	exonic	GRIN3B	.	synonymous SNV	GRIN3B:NM_138690:exon6:c.C2394T:p.G798G	0.001113712	0.952832628	0.04605366	.	0.05632	.	.	.	14513.3031	26.28567	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	81	chr19	1008218	chr19:1008218	C	T	.	PASS	AN=0;DP=81	GT	0/1
chr19	1111964	1111964	C	T	intronic	SBNO2	.	.	.	0.024423765	0.975552528	2.37E-05	.	0.41647	0.11239	-2.2729502	1.250294881	880.95739	5.7817	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	115	chr19	1111964	chr19:1111964	C	T	.	PASS	AN=0;DP=115	GT	0/1
chr19	2037757	2037757	G	A	exonic	MKNK2	.	nonsynonymous SNV	MKNK2:NM_017572:exon14:c.C1226T:p.T409I	9.34E-06	0.777281387	0.222709276	.	0.18067	0.14759	-0.576764155	18.7839113	742.98614	5.41125	0.0	0.912	D	0.062	0.235	B	0.035	0.214	B	.	.	.	1	0.090	N	.	.	.	0.72	0.670	T	-0.85	0.232	N	0.089	0.086	-0.946	0.417	T	0.130	0.440	T	0.030	0.528	D	0.775	0.168	9.312	0.965	0.293	0.391	0.259	N	c	-0.990	-0.972	1.000	0.458	0.732	0.924	0	-0.258	0.123	1.189	0.315	-0.009	0.132	0.870	0.305	0.753	0.322	9.716	0.393	.	.	.	0.5	.	23	chr19	2037757	chr19:2037757	G	A	.	PASS	AN=0;DP=23	GT	0/1
chr19	4097335	4097335	C	T	exonic	MAP2K2	.	nonsynonymous SNV	MAP2K2:NM_030662:exon8:c.G926A:p.G309E	0.863261159	0.136320885	0.000417956	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	0.09	0.319	T	0.975	0.561	D	0.909	0.628	D	0.000	0.843	D	1.000	0.548	D	1.56	0.396	L	-2.99	0.921	D	-2.76	0.585	D	0.574	0.610	0.438	0.897	D	0.770	0.922	D	0.308	0.911	D	1.979	0.299	16.08	0.948	0.250	0.975	0.753	D	c	0.176	0.073	1.000	0.411	0.672	0.522	0	3.38	0.376	4.995	0.634	0.844	0.344	1.000	0.715	0.090	0.185	13.778	0.624	Protein kinase domain|Protein kinase-like domain;Protein kinase domain|Protein kinase-like domain|Serine/threonine/dual specificity protein kinase, catalytic  domain	.	.	0.5	.	17	chr19	4097335	chr19:4097335	C	T	.	PASS	AN=0;DP=17	GT	0/1
chr19	4097342	4097342	C	T	splicing	MAP2K2	NM_030662:exon8:c.920-1G>A	.	.	0.863261159	0.136320885	0.000417956	DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:20358587}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.88489	0.51187	-0.800872469	12.33191791	40.94266	1.19949	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	3.324	0.458	22.9	0.984	0.407	0.996	0.982	D	c	0.832	0.564	1.000	0.747	0.257	0.036	0	3.38	0.376	7.857	0.852	0.844	0.344	1.000	0.715	0.199	0.217	13.778	0.624	.	.	.	0.5	.	17	chr19	4097342	chr19:4097342	C	T	.	PASS	AN=0;DP=17	GT	0/1
chr19	6709644	6709644	C	T	intronic	C3	.	.	.	0.999590151	0.000409849	2.80E-17	DISEASE: Complement component 3 deficiency (C3D) [MIM:613779]: A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. {ECO:0000269|PubMed:7961791}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Macular degeneration, age-related, 9 (ARMD9) [MIM:611378]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:17634448, ECO:0000269|PubMed:24036952}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Hemolytic uremic syndrome atypical 5 (AHUS5) [MIM:612925]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:18796626, ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.; DISEASE: Note=Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.; 	.	.	-1.688698506	2.618542109	457.09361	4.43999	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	39	chr19	6709644	chr19:6709644	C	T	.	PASS	AN=0;DP=39	GT	0/1
chr19	8567371	8567371	G	A	intronic	PRAM1	.	.	.	0.007624896	0.977092731	0.015282373	.	0.07212	0.09413	0.780798785	87.24345364	1485.44258	7.17177	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	96	chr19	8567371	chr19:8567371	G	A	.	PASS	AN=0;DP=96	GT	0/1
chr19	9582037	9582037	G	T	exonic	ZNF560	.	nonsynonymous SNV	ZNF560:NM_152476:exon6:c.C256A:p.Q86K	7.36E-10	0.665805223	0.334194776	.	0.15343	.	-0.462894052	23.62585515	110.60062	2.29006	0.313	0.139	T	0.069	0.223	B	0.005	0.104	B	.	.	.	1	0.090	N	-0.895	0.014	N	3.53	0.049	T	0.2	0.049	N	0.097	0.098	-0.914	0.464	T	0.009	0.030	T	0.001	0.018	T	-1.789	0.011	0.002	0.382	0.026	0.004	0.019	N	c	-1.364	-1.438	0.000	0.012	0.554	0.246	0	-2.46	0.061	-1.236	0.030	-0.670	0.040	0.000	0.063	0.001	0.043	8.133	0.300	.	.	.	0.5	.	26	chr19	9582037	chr19:9582037	G	T	.	PASS	AN=0;DP=26	GT	0/1
chr19	10369847	10369847	G	A	UTR3	MRPL4	NM_146388:c.*433G>A	.	.	1.13E-07	0.335436284	0.664563603	.	0.05217	0.10832	0.198490371	67.30360934	1535.10751	7.28081	.	.	.	.	.	.	.	.	.	.	.	.	1.000	0.240	N	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.057	0.099	3.156	0.686	0.085	0.021	0.062	N	n	0.593	2.945	1.000	0.747	0.205	0.033	1	1.35	0.210	0.370	0.200	0.944	0.532	0.001	0.137	0.019	0.132	7.217	0.250	.	.	.	0.5	.	30	chr19	10369847	chr19:10369847	G	A	.	PASS	AN=0;DP=30	GT	0/1
chr19	10969014	10969014	G	A	exonic	C19orf38	.	synonymous SNV	C19orf38:NM_001136482:exon4:c.G456A:p.K152K	.	.	.	.	.	.	0.591694063	82.45458835	366.41714	4.04947	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	53	chr19	10969014	chr19:10969014	G	A	.	PASS	AN=0;DP=53	GT	0/1
chr19	11725682	11725682	A	G	exonic	ZNF627	.	synonymous SNV	ZNF627:NM_145295:exon3:c.A171G:p.K57K,ZNF627:NM_001290083:exon4:c.A75G:p.K25K	0.005644146	0.989445166	0.004910688	.	0.20136	0.10503	-0.424258538	25.56027365	57.87877	1.53812	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	146	chr19	11725682	chr19:11725682	A	G	62	PASS	AN=2;DP=146	GT	0/1
chr19	12768821	12768821	G	A	intronic	MAN2B1	.	.	.	1.56E-12	0.928196832	0.071803168	DISEASE: Mannosidosis, alpha B, lysosomal (MANSA) [MIM:248500]: A lysosomal storage disease characterized by accumulation of unbranched oligosaccharide chains. This accumulation is expressed histologically as cytoplasmic vacuolation predominantly in the CNS and parenchymatous organs. Depending on the clinical findings at the age of onset, a severe infantile (type I) and a mild juvenile (type II) form of alpha-mannosidosis are recognized. There is considerable variation in the clinical expression with mental retardation, recurrent infections, impaired hearing and Hurler- like skeletal changes being the most consistent abnormalities. {ECO:0000269|PubMed:12718372, ECO:0000269|PubMed:15712269, ECO:0000269|PubMed:22161967, ECO:0000269|PubMed:9158146, ECO:0000269|PubMed:9758606, ECO:0000269|PubMed:9915946}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.06035	0.22441	0.121225147	62.22576079	2735.34889	9.86188	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	277	chr19	12768821	chr19:12768821	G	A	75	PASS	AN=2;DP=277	GT	0/1
chr19	13085229	13085229	C	T	UTR3	DAND5	NM_152654:c.*781C>T	.	.	1.68E-05	0.252738096	0.74724507	.	0.10745	0.20281	-0.029247611	51.40363293	16.50617	0.58379	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	21	chr19	13085229	chr19:13085229	C	T	.	PASS	AN=0;DP=21	GT	0/1
chr19	14530029	14530029	C	T	intronic	DDX39A	.	.	.	0.843485807	0.15639202	0.000122173	.	0.1929	0.12971	-0.580403979	18.58928993	124.14286	2.42456	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	252	chr19	14530029	chr19:14530029	C	T	.	PASS	AN=0;DP=252	GT	0/1
chr19	17531926	17531929	CCCA	-	intronic	MVB12A	.	.	.	0.000679169	0.914542667	0.084778163	.	0.09158	.	0.350995466	74.37485256	188.19304	2.97888	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	78	chr19	17531925	chr19:17531925	TCCCA	T	65	PASS	AN=2;DP=78	GT	0/1
chr19	17734350	17734350	C	T	intronic	UNC13A	.	.	.	0.999986711	1.33E-05	3.94E-18	.	0.20708	.	-1.697674421	2.583156405	1626.22937	7.45646	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.908	0.660	25.0	0.990	0.487	0.783	0.383	D	c	0.887	0.682	0.022	0.134	0.091	0.019	0	3.75	0.421	3.361	0.518	0.780	0.314	1.000	0.715	0.999	0.750	11.462	0.493	.	.	.	0.5	.	98	chr19	17734350	chr19:17734350	C	T	.	PASS	AN=0;DP=98	GT	0/1
chr19	19650454	19650454	A	T	intronic	CILP2	.	.	.	0.000278936	0.999088514	0.000632549	.	0.16316	0.11129	-1.082044518	7.242274121	113.50816	2.31988	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	57	chr19	19650454	chr19:19650454	A	T	.	PASS	AN=0;DP=57	GT	0/1
chr19	36278877	36278877	G	A	exonic	ARHGAP33	.	nonsynonymous SNV	ARHGAP33:NM_001172630:exon21:c.G2918A:p.S973N,ARHGAP33:NM_052948:exon21:c.G2927A:p.S976N	0.21224841	0.787750958	6.32E-07	.	0.40232	0.13342	-1.456898556	3.862939372	201.41522	3.06572	0.179	0.564	T	0.0	0.026	B	0.002	0.063	B	0.518	0.118	N	1.000	0.588	D	0.805	0.203	L	3.11	0.122	T	-0.33	0.162	N	0.019	0.005	-0.985	0.339	T	0.017	0.069	T	0.010	0.254	T	-0.936	0.034	0.022	0.886	0.175	0.181	0.199	N	c	-0.995	-0.929	0.000	0.029	0.706	0.609	0	-1.75	0.076	-0.037	0.120	-0.375	0.066	0.000	0.063	0.902	0.382	5.235	0.147	.	.	.	0.5	.	70	chr19	36278877	chr19:36278877	G	A	.	PASS	AN=0;DP=70	GT	0/1
chr19	36278929	36278929	C	T	exonic	ARHGAP33	.	synonymous SNV	ARHGAP33:NM_001172630:exon21:c.C2970T:p.A990A,ARHGAP33:NM_052948:exon21:c.C2979T:p.A993A	0.21224841	0.787750958	6.32E-07	.	0.40232	0.13342	-1.456898556	3.862939372	201.41522	3.06572	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	60	chr19	36278929	chr19:36278929	C	T	.	PASS	AN=0;DP=60	GT	0/1
chr19	36606592	36606592	C	G	intronic	TBCB	.	.	.	0.405521803	0.585756254	0.008721944	.	0.08922	0.10539	-0.383807564	27.41802312	11.3524	0.40856	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	67	33	chr19	36606592	chr19:36606592	C	G	67	PASS	AN=2;DP=33	GT	0/1
chr19	39034301	39034302	GT	-	splicing	RYR1	NM_000540:exon86:r.spl;NM_001042723:exon85:r.spl	.	.	1.61E-07	0.999999839	2.45E-26	DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775, ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852, ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881, ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716, ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726, ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367, ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571, ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712, ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359, ECO:0000269|PubMed:9066328, ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851, ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10097181, ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081, ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404, ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400, ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524, ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095, ECO:0000269|PubMed:7829078, ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9497245}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:20583297}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a congenital myopathy with benign course. Patients display severe hypotonia and respiratory distress at birth. Unlike other congenital myopathies, the health status constantly improves and patients are minimally affected at adulthood.; 	0.22212	.	-8.291678111	0.005897617	2142.38985	8.51518	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	16	chr19	39034300	chr19:39034300	GGT	G	60	PASS	AN=2;DP=16	GT	0/1
chr19	42401291	42401291	C	A	intronic	ARHGEF1	.	.	.	0.909497464	0.090502526	9.81E-09	.	0.10869	0.1503	-1.837219906	2.070063694	124.73358	2.42844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	118	chr19	42401291	chr19:42401291	C	A	.	PASS	AN=0;DP=118	GT	0/1
chr19	45263023	45263023	C	T	UTR3	BCL3	NM_005178:c.*151C>T	.	.	0.862172685	0.137400478	0.000426837	DISEASE: Note=A chromosomal aberration involving BCL3 may be a cause of B-cell chronic lymphocytic leukemia (B-CLL). Translocation t(14;19)(q32;q13.1) with immunoglobulin gene regions. {ECO:0000269|PubMed:2180580, ECO:0000269|PubMed:7896265}.; 	0.52579	0.28802	.	.	48.07549	1.34896	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	41	chr19	45263023	chr19:45263023	C	T	.	PASS	AN=0;DP=41	GT	0/1
chr19	47575634	47575634	G	C	exonic	ZC3H4	.	nonsynonymous SNV	ZC3H4:NM_015168:exon12:c.C1777G:p.Q593E	0.999999772	2.28E-07	1.41E-17	.	0.40007	.	-1.320975027	4.777070064	637.42325	5.07993	0.018	0.506	D	0.824	0.439	P	0.35	0.410	B	0.229	0.160	U	1.000	0.548	D	1.11	0.288	L	2.22	0.182	T	-0.55	0.168	N	0.346	0.407	-1.110	0.031	T	0.044	0.190	T	0.013	0.325	T	2.615	0.375	20.3	0.988	0.462	0.946	0.616	D	c	0.310	0.370	1.000	0.747	0.713	0.817	0	4.98	0.655	5.545	0.667	0.864	0.376	1.000	0.715	0.724	0.315	17.023	0.863	.	.	.	0.5	75	107	chr19	47575634	chr19:47575634	G	C	75	PASS	AN=2;DP=107	GT	0/1
chr19	48197673	48197673	T	C	exonic	BICRA	.	nonsynonymous SNV	BICRA:NM_015711:exon8:c.T2585C:p.L862P	.	.	.	.	.	.	.	.	.	.	0.003	0.682	D	0.032	0.189	B	0.015	0.162	B	.	.	.	1.000	0.090	N	1.59	0.404	L	1.33	0.350	T	-1.34	0.334	N	0.383	0.443	-1.042	0.166	T	0.054	0.230	T	0.362	0.926	D	0.673	0.158	8.649	0.817	0.133	0.002	0.014	N	c	-0.756	-0.748	0.047	0.147	0.646	0.450	0	1.48	0.218	0.936	0.283	0.835	0.340	0.001	0.137	0.055	0.167	5.257	0.148	.	.	.	0.5	69	130	chr19	48197673	chr19:48197673	T	C	69	PASS	AN=2;DP=130	GT	0/1
chr19	48197686	48197686	C	T	exonic	BICRA	.	synonymous SNV	BICRA:NM_015711:exon8:c.C2598T:p.S866S	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	60	chr19	48197686	chr19:48197686	C	T	.	PASS	AN=0;DP=60	GT	0/1
chr19	48607900	48607900	C	A	exonic	PLA2G4C	.	stopgain	PLA2G4C:NM_001159322:exon4:c.G232T:p.E78X,PLA2G4C:NM_001159323:exon4:c.G202T:p.E68X,PLA2G4C:NM_003706:exon4:c.G202T:p.E68X	4.42E-08	0.946243911	0.053756045	.	0.06112	0.06901	2.447407799	98.56687898	2845.06491	10.08702	.	.	.	.	.	.	.	.	.	0.459	0.124	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6.566	0.903	31	0.993	0.566	0.005	0.025	N	c	-0.068	-0.446	0.001	0.079	0.707	0.730	0	-1.58	0.080	-0.567	0.060	0.679	0.295	0.000	0.063	0.981	0.494	5.502	0.160	Acyl transferase/acyl hydrolase/lysophospholipase|Lysophospholipase, catalytic domain	.	.	0.5	.	15	chr19	48607900	chr19:48607900	C	A	.	PASS	AN=0;DP=15	GT	0/1
chr19	49507487	49507487	A	T	UTR5	RUVBL2	NM_001321190:c.-26A>T	.	.	0.99911008	0.000889912	7.96E-09	.	0.60957	0.54626	-1.023168368	7.944090587	19.53697	0.67025	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	43	chr19	49507487	chr19:49507487	A	T	.	PASS	AN=0;DP=43	GT	0/1
chr19	50764701	50764701	T	-	intronic	MYH14	.	.	.	0.999847921	0.000152079	6.12E-17	DISEASE: Deafness, autosomal dominant, 4A (DFNA4A) [MIM:600652]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:15015131, ECO:0000269|PubMed:16222661}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Peripheral neuropathy, myopathy, hoarseness, and hearing loss (PNMHH) [MIM:614369]: A complex phenotype of progressive peripheral neuropathy and distal myopathy, with later onset of hoarseness and hearing loss. Affected individuals develop distal muscle weakness at a mean age of 10.6 years, followed by progressive atrophy of these muscles. The lower limbs are more severely affected than the upper limbs, and the muscle weakness first affects anterior leg muscles and later posterior leg muscles. {ECO:0000269|PubMed:21480433}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.22477	0.14506	-2.236665977	1.309271054	1826.33006	7.88079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	205	chr19	50764700	chr19:50764700	CT	C	78	PASS	AN=2;DP=205	GT	0/1
chr19	50764716	50764716	C	T	intronic	MYH14	.	.	.	0.999847921	0.000152079	6.12E-17	DISEASE: Deafness, autosomal dominant, 4A (DFNA4A) [MIM:600652]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:15015131, ECO:0000269|PubMed:16222661}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Peripheral neuropathy, myopathy, hoarseness, and hearing loss (PNMHH) [MIM:614369]: A complex phenotype of progressive peripheral neuropathy and distal myopathy, with later onset of hoarseness and hearing loss. Affected individuals develop distal muscle weakness at a mean age of 10.6 years, followed by progressive atrophy of these muscles. The lower limbs are more severely affected than the upper limbs, and the muscle weakness first affects anterior leg muscles and later posterior leg muscles. {ECO:0000269|PubMed:21480433}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.22477	0.14506	-2.236665977	1.309271054	1826.33006	7.88079	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	76	chr19	50764716	chr19:50764716	C	T	.	PASS	AN=0;DP=76	GT	0/1
chr19	51567793	51567793	G	A	intronic	KLK13	.	.	.	0.755462838	0.242478739	0.002058424	.	0.04775	0.09971	-0.159704656	41.90846898	120.56718	2.39208	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	53	chr19	51567793	chr19:51567793	G	A	.	PASS	AN=0;DP=53	GT	0/1
chr19	53905388	53905388	A	T	exonic	ZNF765	.	nonsynonymous SNV	ZNF765:NM_001040185:exon3:c.A86T:p.Q29L	9.05E-10	0.043562588	0.956437411	.	0.09639	.	0.733063566	86.27034678	339.26241	3.9063	0.001	0.784	D	0.992	0.629	D	0.932	0.650	D	.	.	.	1	0.090	N	4.51	0.990	H	2.98	0.094	T	-5.24	0.839	D	0.662	0.674	-0.922	0.454	T	0.152	0.482	T	0.002	0.030	T	3.246	0.449	22.8	0.982	0.388	0.643	0.321	D	c	0.301	-0.045	0.001	0.082	0.672	0.522	0	1.63	0.228	2.134	0.415	0.585	0.286	0.882	0.308	0.007	0.100	6.588	0.217	Krueppel-associated box	.	.	0.5	.	60	chr19	53905388	chr19:53905388	A	T	.	PASS	AN=0;DP=60	GT	0/1
chr20	2320599	2320599	G	A	exonic	TGM3	.	nonsynonymous SNV	TGM3:NM_003245:exon12:c.G1900A:p.G634R	9.87E-06	0.984994274	0.014995859	.	0.35958	0.21918	-0.211293113	37.76244397	1529.88306	7.26777	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.629	D	1.000	0.520	D	3.32	0.909	M	0.12	0.611	T	-7.58	0.953	D	0.93	0.923	-0.039	0.815	T	0.433	0.774	T	0.147	0.830	D	6.132	0.845	28.4	0.999	0.987	0.911	0.525	D	c	0.756	0.678	0.151	0.174	0.516	0.203	0	5.26	0.734	5.717	0.679	1.044	0.665	1.000	0.715	0.995	0.604	14.381	0.663	Immunoglobulin-like fold|Transglutaminase, C-terminal	.	.	0.5	.	80	chr20	2320599	chr20:2320599	G	A	.	PASS	AN=0;DP=80	GT	0/1
chr20	23667683	23667683	C	G	intronic	CST4	.	.	.	7.30E-06	0.161904959	0.838087741	.	0.09154	0.1077	0.262810045	70.43524416	20.08609	0.68634	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	59	chr20	23667683	chr20:23667683	C	G	51	PASS	AN=2;DP=59	GT	0/1
chr20	33147196	33147196	G	A	exonic	MAP1LC3A	.	nonsynonymous SNV	MAP1LC3A:NM_032514:exon3:c.G142A:p.D48N,MAP1LC3A:NM_181509:exon4:c.G154A:p.D52N	0.739731535	0.249075138	0.011193327	.	0.09841	0.09617	-0.009020804	52.8544468	1.17647	0.03321	0.004	0.912	D	0.001	0.131	B	0.04	0.225	B	0.000	0.843	D	1	0.810	D	2.965	0.855	M	0.52	0.553	T	-4.66	0.794	D	0.117	0.130	-0.626	0.638	T	0.239	0.607	T	0.085	0.745	D	4.796	0.644	24.8	0.998	0.906	0.965	0.692	D	c	0.285	0.409	1.0	0.983	0.726	0.872	0	5.08	0.682	9.908	0.986	0.923	0.433	1.000	0.715	0.998	0.697	18.058	0.892	Ubiquitin-related domain	.	.	0.5	.	74	chr20	33147196	chr20:33147196	G	A	.	PASS	AN=0;DP=74	GT	0/1
chr20	33972884	33972884	G	A	intronic	UQCC1	.	.	.	0.004854425	0.989054215	0.00609136	.	0.54483	0.10131	0.483275131	79.25218212	117.95061	2.36137	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chr20	33972884	chr20:33972884	G	A	.	PASS	AN=0;DP=64	GT	0/1
chr20	56089870	56089870	T	-	intronic	CTCFL	.	.	.	0.783031842	0.216955804	1.24E-05	.	0.11608	0.09123	1.181302384	92.80490682	316.39761	3.77775	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	14	chr20	56089869	chr20:56089869	GT	G	50	PASS	AN=2;DP=14	GT	0/1
chr20	62319558	62319618	TGCCCATCCTGGATCCTGGACCCCTGCTCCCAAGAGCTGGTAGGGAACCCTGCAGACATCC	-	ncRNA_intronic	RTEL1-TNFRSF6B	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.34	39	chr20	62319557	chr20:62319557	GTGCCCATCCTGGATCCTGGACCCCTGCTCCCAAGAGCTGGTAGGGAACCCTGCAGACATCC	G	10.34	PASS	AN=0;DP=39	GT	0/1
chr21	15988212	15988212	-	G	intronic	LOC388813	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	90	98	chr21	15988212	chr21:15988212	A	AG	90	PASS	AN=2;DP=98	GT	0/1
chr21	17236606	17236606	C	T	exonic	USP25	.	nonsynonymous SNV	USP25:NM_013396:exon19:c.C2357T:p.A786V,USP25:NM_001283042:exon20:c.C2453T:p.A818V,USP25:NM_001283041:exon21:c.C2567T:p.A856V	0.990130458	0.009869542	7.96E-12	.	0.1656	0.10985	-0.905656269	10.12031139	259.94554	3.46398	0.007	0.614	D	0.078	0.286	B	0.087	0.343	B	0.004	0.343	N	0.979	0.810	D	1.995	0.543	M	1.86	0.245	T	-2.41	0.545	N	0.194	0.238	-0.694	0.607	T	0.291	0.663	T	0.010	0.265	T	4.288	0.574	24.0	0.998	0.873	0.968	0.708	D	c	0.368	0.469	1.000	0.747	0.732	0.924	0	5.62	0.857	4.625	0.607	0.935	0.490	1.000	0.715	0.993	0.574	20.011	0.974	.	.	.	0.5	.	24	chr21	17236606	chr21:17236606	C	T	.	PASS	AN=0;DP=24	GT	0/1
chr21	30338207	30338207	G	A	exonic	LTN1	.	nonsynonymous SNV	LTN1:NM_015565:exon11:c.C2281T:p.L761F	0.83271401	0.16728599	1.69E-11	.	0.63029	0.09925	0.26079244	70.06369427	4364.96083	13.18197	0.229	0.183	T	0.0	0.026	B	0.0	0.013	B	0.933	0.075	N	0.954	0.264	N	0.985	0.251	L	2.18	0.679	T	-1.3	0.326	N	0.047	0.028	-1.029	0.207	T	0.111	0.398	T	0.016	0.377	T	1.278	0.218	12.15	0.963	0.289	0.462	0.275	N	c	-0.739	-0.632	0.781	0.238	0.707	0.730	0	-1.52	0.081	0.204	0.170	0.031	0.150	0.993	0.376	0.991	0.552	1.593	0.025	Armadillo-type fold	.	.	0.5	.	74	chr21	30338207	chr21:30338207	G	A	.	PASS	AN=0;DP=74	GT	0/1
chr21	36265324	36265324	T	-	intronic	RUNX1	.	.	.	0.449323607	0.549373498	0.001302896	DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.; DISEASE: Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; DISEASE: Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. {ECO:0000269|PubMed:10508512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; 	0.71814	0.72461	-0.227663163	37.11370606	85.67689	1.97553	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	22	chr21	36265323	chr21:36265323	CT	C	43	PASS	AN=2;DP=22	GT	0/1
chr21	40684799	40684799	C	T	exonic	BRWD1	.	nonsynonymous SNV	BRWD1:NM_001007246:exon4:c.G166A:p.G56S,BRWD1:NM_018963:exon4:c.G166A:p.G56S,BRWD1:NM_033656:exon4:c.G166A:p.G56S	0.999999462	5.38E-07	6.53E-23	.	0.64569	0.10719	-0.821412236	11.77164426	5050.46205	14.54368	0.004	0.654	D	0.737	0.899	P	0.215	0.971	B	0.000	0.629	D	1.000	0.588	D	3.095	0.878	M	1.14	0.384	T	-5.16	0.869	D	0.549	0.585	-0.464	0.699	T	0.263	0.634	T	0.718	0.977	D	6.777	0.923	32	0.997	0.796	0.808	0.401	D	c	0.507	0.423	1.000	0.747	0.658	0.486	0	3.06	0.342	6.150	0.714	0.028	0.149	1.000	0.715	0.999	0.750	12.682	0.561	.	.	.	0.5	.	124	chr21	40684799	chr21:40684799	C	T	.	PASS	AN=0;DP=124	GT	0/1
chr21	45999772	45999772	T	C	exonic	KRTAP10-5	.	nonsynonymous SNV	KRTAP10-5:NM_198694:exon1:c.A684G:p.I228M	8.25E-05	0.321633815	0.678283707	.	.	.	1.953079981	97.54659118	4100.88283	12.70549	0.047	0.403	D	0.256	0.296	B	0.262	0.378	B	.	.	.	1	0.810	D	-0.05	0.049	N	5.78	0.007	T	-1.45	0.356	N	0.116	0.130	-0.887	0.492	T	0.002	0.007	T	0.008	0.201	T	1.241	0.214	11.96	0.938	0.232	0.035	0.086	N	c	-0.684	-0.626	0.000	0.070	0.487	0.133	0	1.72	0.234	-0.098	0.109	-0.366	0.067	0.049	0.212	0.062	0.172	3.773	0.081	.	.	.	0.5	63	100	chr21	45999772	chr21:45999772	T	C	63	PASS	AN=2;DP=100	GT	0/1
chr21	46554688	46554688	C	A	intronic	ADARB1	.	.	.	0.843939347	0.155939433	0.00012122	.	0.28156	0.13431	-0.800872469	12.33191791	35.57047	1.07201	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	47	chr21	46554688	chr21:46554688	C	A	.	PASS	AN=0;DP=47	GT	0/1
chr21	46945700	46945700	C	-	intronic	SLC19A1	.	.	.	0.0123881	0.952273227	0.035338672	.	0.0749	.	-0.286522835	33.47487615	1149.843	6.46099	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	72	chr21	46945699	chr21:46945699	TC	T	65	PASS	AN=2;DP=72	GT	0/1
chr21	47976820	47976820	T	-	intronic	DIP2A	.	.	.	0.726099074	0.273900925	1.67E-09	.	0.20513	0.09801	-2.776863601	0.678225997	1074.58254	6.28283	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	15	chr21	47976819	chr21:47976819	CT	C	43	PASS	AN=2;DP=15	GT	0/1
chr22	24658397	24658397	C	T	ncRNA_exonic	POM121L9P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	68	chr22	24658397	chr22:24658397	C	T	.	PASS	AN=0;DP=68	GT	0/1
chr22	24665292	24665292	T	C	intergenic	POM121L9P;SPECC1L-ADORA2A	dist=3800;dist=1493	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	47	chr22	24665292	chr22:24665292	T	C	.	PASS	AN=0;DP=47	GT	0/1
chr22	30795595	30795595	C	T	intronic	SEC14L2	.	.	.	4.31E-05	0.958730605	0.041226246	.	0.27976	0.12613	0.238945317	69.20853975	3585.08728	11.58105	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	76	chr22	30795595	chr22:30795595	C	T	.	PASS	AN=0;DP=76	GT	0/1
chr22	31322631	31322631	G	A	ncRNA_exonic	MORC2-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr22	31322631	chr22:31322631	G	A	.	PASS	AN=0;DP=45	GT	0/1
chr22	31672777	31672777	C	-	exonic	LIMK2	.	frameshift deletion	LIMK2:NM_001031801:exon15:c.1712delC:p.A575Pfs*14	0.008440401	0.99099989	0.000559709	.	0.26618	0.2057	0.113945049	62.14319415	767.32501	5.48678	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	66	chr22	31672776	chr22:31672776	GC	G	51	PASS	AN=2;DP=66	GT	0/1
chr22	37455498	37455498	C	T	intronic	KCTD17	.	.	.	0.051116993	0.860718465	0.088164542	.	0.12828	0.10832	0.082802743	60.09082331	544.15613	4.74685	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	100	chr22	37455498	chr22:37455498	C	T	64	PASS	AN=2;DP=100	GT	0/1
chr22	38641968	38641968	A	T	exonic	TMEM184B	.	nonsynonymous SNV	TMEM184B:NM_001195071:exon3:c.T331A:p.F111I,TMEM184B:NM_012264:exon3:c.T331A:p.F111I,TMEM184B:NM_001195072:exon4:c.T133A:p.F45I	0.878340976	0.121351922	0.000307103	.	0.33713	.	-0.53631094	20.53550366	24.77878	0.81381	0.001	0.784	D	0.792	0.427	P	0.714	0.528	P	0.000	0.843	D	1	0.810	D	2.05	0.567	M	0.98	0.421	T	-5.53	0.892	D	0.793	0.783	-0.887	0.492	T	0.155	0.487	T	0.048	0.634	D	6.083	0.838	28.2	0.991	0.534	0.993	0.934	D	c	0.491	0.515	1.000	0.747	0.732	0.924	0	4.53	0.548	9.198	0.941	1.183	0.905	1.000	0.715	1.000	0.888	13.892	0.631	.	.	.	0.5	58	80	chr22	38641968	chr22:38641968	A	T	58	PASS	AN=2;DP=80	GT	0/1
chr22	38901929	38901929	G	A	intronic	DDX17	.	.	.	.	.	.	.	0.95209	0.27727	-0.516085732	21.20193442	42.19846	1.22768	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	93	chr22	38901929	chr22:38901929	G	A	.	PASS	AN=0;DP=93	GT	0/1
chr22	39421052	39421052	C	T	intronic	APOBEC3D	.	.	.	2.36E-05	0.912736699	0.087239749	.	.	0.04922	-0.157884861	42.05590941	49.3236	1.37327	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	95	chr22	39421052	chr22:39421052	C	T	.	PASS	AN=0;DP=95	GT	0/1
chr22	40666253	40666253	G	C	exonic	TNRC6B	.	synonymous SNV	TNRC6B:NM_001162501:exon6:c.G2934C:p.T978T,TNRC6B:NM_001024843:exon8:c.G693C:p.T231T	0.999999803	1.97E-07	4.09E-19	.	0.5184	0.11889	-1.807947733	2.199811276	2219.15225	8.67424	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	73	chr22	40666253	chr22:40666253	G	C	65	PASS	AN=2;DP=73	GT	0/1
chr22	42993761	42993761	C	T	intronic	POLDIP3	.	.	.	0.832319947	0.167650206	2.98E-05	.	0.12164	.	0.264628794	70.5178108	852.50931	5.70421	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	57	chr22	42993761	chr22:42993761	C	T	.	PASS	AN=0;DP=57	GT	0/1
chr22	45601764	45601764	C	T	exonic	KIAA0930	.	synonymous SNV	KIAA0930:NM_001009880:exon3:c.G246A:p.V82V,KIAA0930:NM_015264:exon3:c.G261A:p.V87V	0.815289887	0.18451819	0.000191924	.	0.16326	0.09256	-0.977252525	8.799245105	22.55837	0.75396	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	43	chr22	45601764	chr22:45601764	C	T	.	PASS	AN=0;DP=43	GT	0/1
chr22	45601767	45601767	C	T	exonic	KIAA0930	.	synonymous SNV	KIAA0930:NM_001009880:exon3:c.G243A:p.E81E,KIAA0930:NM_015264:exon3:c.G258A:p.E86E	0.815289887	0.18451819	0.000191924	.	0.16326	0.09256	-0.977252525	8.799245105	22.55837	0.75396	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr22	45601767	chr22:45601767	C	T	.	PASS	AN=0;DP=45	GT	0/1
chr22	45749842	45749842	G	A	intronic	SMC1B	.	.	.	0.986578246	0.013421754	3.42E-12	.	0.51288	0.08472	0.271907863	70.73012503	4981.23034	14.38844	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr22	45749842	chr22:45749842	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr22	50687619	50687619	C	T	intronic	HDAC10	.	.	.	3.28E-12	0.149158506	0.850841494	.	0.10737	0.15425	-0.172654315	40.63458363	807.74818	5.59736	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	111	chr22	50687619	chr22:50687619	C	T	.	PASS	AN=0;DP=111	GT	0/1
chr22	50720031	50720031	C	T	exonic	PLXNB2	.	synonymous SNV	PLXNB2:NM_012401:exon21:c.G3486A:p.Q1162Q	0.992862471	0.007137529	1.47E-13	.	0.21876	0.12373	-3.297942414	0.418730833	992.83256	6.07108	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	40	chr22	50720031	chr22:50720031	C	T	.	PASS	AN=0;DP=40	GT	0/1
chrX	19363864	19363866	CCC	-	intronic	PDHA1	.	.	.	0.992090139	0.007908215	1.65E-06	DISEASE: Pyruvate dehydrogenase E1-alpha deficiency (PDHAD) [MIM:312170]: An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis. {ECO:0000269|PubMed:1293379, ECO:0000269|PubMed:1338114, ECO:0000269|PubMed:1551669, ECO:0000269|PubMed:1909401, ECO:0000269|PubMed:7545958, ECO:0000269|PubMed:7573035, ECO:0000269|PubMed:7757088, ECO:0000269|PubMed:7887409, ECO:0000269|PubMed:7967473, ECO:0000269|PubMed:8032855, ECO:0000269|PubMed:8504306, ECO:0000269|PubMed:8664900, ECO:0000269|PubMed:8844217, ECO:0000269|PubMed:9671272}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.27813	0.5595	0.170987912	65.5579146	381.13932	4.11483	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	33	chrX	19363863	chrX:19363863	TCCC	T	44	PASS	AN=2;DP=33	GT	0/1
chrX	41092075	41092075	G	T	UTR3	USP9X	NM_001039591:c.*298G>T;NM_001039590:c.*298G>T	.	.	1	2.36E-11	2.78E-27	.	0.58131	0.10304	-1.618506764	2.925218212	35.92323	1.07855	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chrX	41092075	chrX:41092075	G	T	.	PASS	AN=0;DP=46	GT	0/1
chrX	75393057	75393057	T	-	intronic	PBDC1	.	.	.	0.845464415	0.151771167	0.002764418	.	0.05536	0.07658	-0.053113545	49.38664779	6.77226	0.24999	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	19	chrX	75393056	chrX:75393056	CT	C	42	PASS	AN=2;DP=19	GT	0/1
chrX	96684735	96684735	A	C	exonic	DIAPH2	.	synonymous SNV	DIAPH2:NM_006729:exon26:c.A3232C:p.R1078R,DIAPH2:NM_007309:exon26:c.A3232C:p.R1078R	0.9991191	0.0008809	6.44E-11	DISEASE: Premature ovarian failure 2A (POF2A) [MIM:300511]: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. {ECO:0000269|PubMed:9497258}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.56881	0.27299	-0.999300439	8.368719038	38.85136	1.15117	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	18	chrX	96684735	chrX:96684735	A	C	.	PASS	AN=0;DP=18	GT	0/1
chrX	109561058	109561060	CCG	-	exonic	AMMECR1	.	nonframeshift deletion	AMMECR1:NM_001025580:exon1:c.240_242del:p.G82del,AMMECR1:NM_015365:exon1:c.240_242del:p.G82del	0.910792997	0.088538552	0.00066845	DISEASE: Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR) [MIM:300194]: A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, sensorineural hearing loss, mental retardation, midface hypoplasia and elliptocytosis. {ECO:0000269|PubMed:10049589}. Note=The gene represented in this entry may be involved in disease pathogenesis.; 	0.89609	0.33817	-0.09720619	46.20193442	15.37972	0.5519	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	30	chrX	109561057	chrX:109561057	CCCG	C	64	PASS	AN=2;DP=30	GT	0/1
chrX	128876167	128876167	C	T	intronic	XPNPEP2	.	.	.	1.69E-06	0.963806586	0.036191722	DISEASE: Angioedema induced by ACE inhibitors (AEACEI) [MIM:300909]: A potentially life-threatening side effect of ACE inhibitors that appears in a subset of patients taking these drugs for hypertension and cardiovascular disease treatment. AEACEI is characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe. {ECO:0000269|PubMed:16175507, ECO:0000269|PubMed:20625347, ECO:0000269|PubMed:21898657}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.44594	0.13793	-0.376526807	28.10804435	570.24498	4.84534	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	191	chrX	128876167	chrX:128876167	C	T	.	PASS	AN=0;DP=191	GT	0/1
chrX	131352206	131352206	G	A	intronic	RAP2C	.	.	.	0.212765647	0.648042038	0.139192315	.	0.61236	0.13588	-0.009020804	52.8544468	1.19806	0.035	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chrX	131352206	chrX:131352206	G	A	.	PASS	AN=0;DP=38	GT	0/1
chrX	150347552	150347552	C	-	intronic	GPR50	.	.	.	0.445210115	0.525810593	0.028979292	.	0.08612	0.10006	-0.378346116	28.01368247	1098.54685	6.34364	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	116	401	chrX	150347551	chrX:150347551	TC	T	116	PASS	AN=2;DP=401	GT	0/1
chrX	150347647	150347647	G	A	intronic	GPR50	.	.	.	0.445210115	0.525810593	0.028979292	.	0.08612	0.10006	-0.378346116	28.01368247	1098.54685	6.34364	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	64	chrX	150347647	chrX:150347647	G	A	.	PASS	AN=0;DP=64	GT	0/1
chrX	153282349	153282349	C	-	intronic	IRAK1	.	.	.	0.994301924	0.005697338	7.38E-07	.	0.17579	0.59389	0.687150476	85.17928757	144.97421	2.62306	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	38	chrX	153282348	chrX:153282348	GC	G	44	PASS	AN=2;DP=38	GT	0/1
